.

Orthopaedic Surgery - Hemangioma

Basics

Hemangioma is a benign vascular lesion that may arise within bone or soft tissue.

In orthopaedic practice, these lesions may involve the axial or appendicular skeleton as well as the surrounding soft tissues.

Many lesions historically labeled hemangiomas, particularly in soft tissue, are now more precisely categorized according to modern vascular-anomaly terminology, but the term remains widely used in musculoskeletal literature.

Age

Hemangiomas can occur at any age, although osseous lesions are most commonly diagnosed during the middle decades of life.

Epidemiology

Hemangiomas are relatively uncommon as symptomatic orthopaedic lesions.

No major difference in prevalence between males and females has been consistently demonstrated.

Risk Factors

No specific environmental or acquired risk factors are known.

Genetics

There is no established hereditary pattern for the typical musculoskeletal hemangioma.

Etiology

The exact cause is unknown.

These lesions are considered benign and nonmetastatic.

Some pathologists regard certain vascular lesions of this type as hamartomatous malformations rather than true neoplasms.

Diagnosis

Signs and Symptoms

Clinical presentation depends on whether the lesion involves bone or soft tissue.

Osseous Hemangioma

A bone lesion may present with a slowly progressive, poorly localized ache or localized swelling.

Many lesions are asymptomatic and found incidentally.

Occasionally, weakening of the involved bone may lead to a pathologic fracture.

Vertebral Hemangioma

Vertebral hemangiomas are commonly incidental findings.

More aggressive lesions can rarely produce vertebral expansion, collapse, epidural extension, pain, or neurologic compromise.

Soft-Tissue Hemangioma

Soft-tissue vascular lesions often present with intermittent swelling, fullness, or a soft mass.

Pain may be absent or mild.

Symptoms and size may fluctuate depending on limb position and venous filling.

Physical Examination

Soft-tissue lesions may feel soft, compressible, fluctuant, or springy on palpation.

Examination is often most informative when the affected limb is placed in a dependent position.

Positional Enlargement

Because the lesion contains vascular channels that fill with blood, it may enlarge when the extremity is dependent and partially collapse with elevation or compression.

After palpation, the lesion may refill gradually.

Laboratory Tests

There are no specific serum laboratory studies that establish the diagnosis of a hemangioma.

Laboratory tests are obtained only when another diagnosis is being considered.

Imaging

Soft-Tissue Lesions

Plain radiographs may be normal or may show indirect evidence of a vascular lesion.

Some lesions produce erosion or remodeling of adjacent bone.

Phleboliths

Rounded calcified thrombi, known as phleboliths, may be visible within soft-tissue vascular lesions.

They are seen in a substantial minority of cases and strongly support a venous vascular lesion when present.

MRI

MRI is the preferred modality for defining the extent and internal characteristics of a soft-tissue vascular lesion.

Gadolinium-enhanced imaging is particularly useful.

MRI Appearance

Typical findings may include serpiginous vascular channels with contrast enhancement.

Lesions may contain substantial fat, producing high signal on T1-weighted images.

Blood-filled vascular spaces and slow-flow components may also produce high signal on fluid-sensitive or T2-weighted sequences.

Osseous Hemangioma

Bone hemangiomas may be solitary or multiple.

They are often expansile and trabeculated and generally produce little or no aggressive periosteal reaction.

Vertebral Radiographic Appearance

A classic vertebral hemangioma demonstrates thickened vertical trabeculae.

On radiographs this produces a “corduroy” or vertically striated appearance.

CT Appearance

Axial CT may show thickened trabeculae seen end-on, creating the characteristic “polka-dot” appearance.

Other Radiographic Patterns

The imaging appearance can vary considerably.

Lesions may appear:

Trabeculated, expansile, “soap-bubble,” osteopenic, or predominantly lytic.

The absence of an aggressive periosteal response and the presence of characteristic internal trabeculation can help suggest the diagnosis.

Pathological Findings

Grossly, these lesions may appear markedly vascular and bloody.

Residual or thickened trabecular bone often passes through the lesion.

Microscopy

Histologic examination typically shows numerous thin-walled vascular channels containing red blood cells.

Depending on the lesion type, channels may be capillary-sized or larger.

Lymphatic channels may also be prominent in some vascular malformations.

Differential Diagnosis

Important considerations include:

Multiple myeloma, infection, simple or aneurysmal bone cyst, primary malignant bone tumor, and metastatic disease.

Other vascular tumors or malformations may also need to be distinguished histologically and radiographically.

Treatment

General Principles

Most asymptomatic osseous hemangiomas do not require treatment.

Management is determined by symptoms, location, structural risk, neurologic involvement, and diagnostic certainty.

Soft-Tissue Lesions

Soft-tissue vascular lesions may recur after surgical excision, particularly when they are diffuse or infiltrative.

For this reason, surgery is avoided when an effective less invasive treatment is available.

Compression

Compression garments or dressings may reduce swelling and discomfort in selected superficial or low-flow lesions.

Sclerotherapy

Image-guided sclerotherapy is commonly used for appropriate symptomatic venous malformations.

Agents vary by lesion characteristics and specialist preference.

Historically, alcohol has been used as a powerful sclerosant, although treatment requires experienced interventional specialists because significant complications are possible.

Osseous Lesions

Hemangiomas of bone rarely require surgical treatment when they are asymptomatic and structurally stable.

Observation is usually appropriate.

Physical Therapy

Physical therapy has no direct role in treating the vascular lesion itself.

It may occasionally be used for rehabilitation when weakness or functional limitation results from associated surgery or fracture.

Surgery

Surgery should generally be reserved for selected situations, such as:

Diagnostic uncertainty requiring biopsy, pathologic fracture, structural compromise, progressive neurologic deficit, severe refractory symptoms, or failure of other treatments.

Biopsy

Biopsy of a suspected vascular lesion requires careful planning because these tumors may bleed significantly.

The imaging appearance should be reviewed thoroughly before biopsy, and the procedure should be coordinated with an experienced musculoskeletal tumor team when diagnosis is uncertain.

Follow-Up

Prognosis

The overall prognosis is excellent because typical hemangiomas are benign and lack metastatic potential.

Recurrence

Local recurrence may occur, particularly in incompletely treated soft-tissue lesions.

Recurrence does not imply malignant transformation.

Complications

Pathologic Fracture

An osseous lesion that substantially weakens bone may rarely produce a pathologic fracture.

Neurologic Compromise

Aggressive vertebral lesions can occasionally cause spinal canal compromise and neurologic deficits.

Bleeding

Because these lesions are vascular, operative or biopsy procedures may be complicated by substantial hemorrhage.

Patient Monitoring

Most stable bone lesions require only observation unless symptoms, fracture risk, or structural changes develop.

Soft-tissue lesions may be followed with serial clinical examinations and MRI, particularly when symptoms or size are changing.

Follow-up intervals such as every 3–6 months initially may be appropriate for symptomatic or recently treated lesions, with longer intervals once stability is established.

Orthopaedic Surgery - Heel Sores

Basics

Heel sores are pressure-related injuries of the skin and underlying tissues over the calcaneus, usually caused by prolonged loading of the heel.

They occur most often in patients who are bedridden, nonambulatory, critically ill, neurologically impaired, or otherwise unable to reposition the lower extremities independently.

Heel pressure injuries can also develop beneath a lower-extremity cast when padding is inadequate or persistent pressure is concentrated over the posterior heel.

Synonyms

Common terms include heel pressure ulcer, heel ulcer, pressure sore, bedsore, and decubitus ulcer.

The modern term pressure injury is often preferred because significant underlying tissue damage may exist before an open ulcer is visible.

Classification

Pressure injuries are commonly staged according to the depth of tissue involvement.

Stage I

Stage I consists of intact skin with persistent nonblanchable erythema.

The skin may also be painful, warmer or cooler than surrounding tissue, or altered in consistency.

This stage represents early pressure-related injury before actual skin loss has occurred.

Stage II

Stage II involves partial-thickness loss of skin, affecting the epidermis and sometimes part of the dermis.

It may appear as a shallow ulcer, blister, crack, or superficial area of skin breakdown.

Stage III

Stage III represents full-thickness skin loss extending into the subcutaneous tissues.

The ulcer may reach the level of the underlying fascia but does not expose deeper structures such as tendon or bone.

Stage IV

Stage IV pressure injury consists of extensive full-thickness tissue destruction with exposure or direct involvement of bone, tendon, muscle, joint, or other deep structures.

These lesions carry a substantial risk of deep infection and osteomyelitis.

Geriatric Considerations

Older adults are at particularly high risk because of thinner skin, reduced soft-tissue padding, impaired circulation, frailty, and a greater likelihood of immobility or hospitalization.

Comorbidities such as diabetes, neuropathy, peripheral vascular disease, and poor nutrition further increase risk.

Prevention

Prevention is the most important aspect of management.

Early recognition and removal of pressure can prevent superficial tissue injury from progressing to deep ulceration.

Repositioning

Bed-bound patients should be repositioned frequently so that prolonged pressure is not maintained over the same area.

Heel Off-Loading

The heels should be elevated or floated completely off the mattress using appropriate positioning devices or pillows that support the lower leg without concentrating pressure behind the heel.

Cast Precautions

Patients wearing casts should not rest the casted heel continuously on a firm surface.

Any new heel pain, burning, numbness, or pressure sensation beneath a cast should prompt immediate evaluation.

Epidemiology

Heel pressure ulcers are among the more common complications encountered in postoperative, rehabilitative, and long-term-care settings.

They occur particularly frequently in elderly, debilitated, neurologically impaired, or immobilized patients.

Incidence

In hospitalized populations, heel ulcers have been reported in up to approximately 18% of patients in some series.

The exact incidence varies substantially according to patient population and preventive practices.

Risk Factors

Important risk factors include:

Diabetes mellitus, peripheral neuropathy, peripheral vascular disease, malnutrition, immobility, bed-bound status, paralysis, and prolonged postoperative inactivity.

Etiology

Heel sores develop when sustained pressure and shear forces compromise the small blood vessels supplying the skin and soft tissues over the calcaneus.

Pressure

The posterior heel contains relatively little soft-tissue padding between the skin and bone.

When the heel remains against a mattress, cast, or other surface for prolonged periods, local capillary pressure may exceed tissue perfusion pressure.

This produces ischemia, cellular injury, and eventually necrosis.

Shear

Shear forces generated when the limb slides across a bed or within a cast can distort small vessels and further impair blood flow.

Neuropathy

Patients with reduced sensation may not feel the pain that normally prompts repositioning.

As a result, tissue injury may progress substantially before it is recognized.

Vascular Disease

Peripheral arterial disease reduces tissue perfusion and limits the ability of the wound to heal.

Cast-Related Pressure

Pressure injuries may occur beneath casts because of inadequate padding, focal pressure points, swelling, or prolonged resting of the heel against the cast surface.

Associated Conditions

Common associated conditions include:

Paralysis, diabetes mellitus, sensory loss or peripheral neuropathy, contractures, vascular disease, and severe immobility.

Diagnosis

Diagnosis is based primarily on history and direct inspection of the heel.

At-risk patients require repeated skin checks because the earliest stage may be subtle.

History

The lesion may initially present with heel pain, tenderness, burning, or a soft or boggy sensation before visible ulceration develops.

Patients with neuropathy may have no warning pain at all.

High-Risk Patients

Special attention should be given to patients who are:

Bed-bound, postoperative, in an intensive care unit, neurologically impaired, diabetic, neuropathic, malnourished, or immobilized in a cast or brace.

Physical Examination

Inspection

The heel should be inspected for:

Erythema, discoloration, blistering, cracks, skin separation, ulceration, eschar, drainage, or deeper tissue exposure.

Nonblanching Discoloration

A red, maroon, or purple area that does not blanch with pressure is concerning for pressure-related tissue injury.

Persistent discoloration may precede visible skin breakdown.

Tenderness

The heel may be tender before major skin changes develop.

Tenderness in an immobilized or casted patient should therefore be taken seriously.

Advanced Ulcers

More advanced lesions may expose subcutaneous tissue, tendon, muscle, or bone.

The true depth of an ulcer can sometimes be difficult to determine when necrotic tissue or eschar covers the base.

Evaluation for Infection

The wound should be examined for:

Surrounding erythema, warmth, swelling, purulent drainage, malodor, fluctuance, or spreading cellulitis.

Systemic symptoms such as fever or malaise raise further concern for deeper infection.

Joint Involvement

Pain with ankle or hindfoot range of motion may suggest extension into a nearby joint and should raise concern for septic arthritis or deep infection.

Neurologic Examination

A complete motor and sensory examination should be performed.

Loss of protective sensation substantially increases the risk of progression and recurrence.

Vascular Examination

Pulses, capillary refill, skin temperature, and other indicators of limb perfusion should be evaluated.

Poor arterial supply may prevent healing and may alter the surgical plan.

Laboratory Tests

Laboratory studies are guided by clinical suspicion.

Suspected Infection

When infection is suspected, appropriate tests may include:

Complete blood count with differential, erythrocyte sedimentation rate, and C-reactive protein.

Blood cultures may be indicated in patients with systemic illness.

Nutrition

When poor nutritional status is suspected, evaluation may include serum albumin, prealbumin, and broader nutritional assessment.

Laboratory values should be interpreted within the overall clinical context.

Imaging

Plain Radiographs

AP and lateral radiographs of the foot and ankle can help identify underlying bone destruction, fracture, foreign material, or advanced osteomyelitis.

Early superficial pressure injuries usually produce no radiographic abnormalities.

MRI

MRI is particularly useful when osteomyelitis, deep abscess, or extension into adjacent soft tissues is suspected.

It is substantially more sensitive than plain radiography for early marrow abnormalities.

Nuclear Medicine Imaging

Tagged white blood cell studies or other nuclear medicine imaging may be used when the diagnosis of osteomyelitis remains uncertain or MRI cannot be performed.

Debridement and Diagnostic Assessment

Necrotic tissue may need to be removed to determine the actual depth and extent of the ulcer.

Debridement also reduces devitalized tissue that can support bacterial growth and interfere with healing.

Pathological Findings

The fundamental pathologic mechanism is ischemic tissue necrosis caused by prolonged pressure.

Persistent ischemia damages the skin and underlying soft tissues, ultimately producing ulceration.

Infection

In chronically debilitated, diabetic, or neuropathic patients, open ulcers can become infected readily.

Progression may lead to cellulitis, abscess formation, osteomyelitis, or septic arthritis.

Differential Diagnosis

Important alternative or associated diagnoses include:

Osteomyelitis, soft-tissue abscess, cellulitis, fracture, and septic arthritis.

Other causes of heel ulceration, including arterial, neuropathic, and traumatic wounds, should also be considered.

Treatment

General Principles

Treatment begins with complete pressure relief, wound assessment, optimization of perfusion and nutrition, infection control when necessary, and appropriate wound care.

Prevention remains more effective than treatment of an established ulcer.

Pressure Off-Loading

Pressure must be removed from the affected heel.

This can be accomplished with heel-suspension devices, pillows positioned under the calf, specialty mattresses, or other off-loading systems.

Foot Care

Patients with diabetes or neuropathy should perform regular skin inspection and wear appropriately fitted shoes that avoid focal pressure.

Daily Inspection

The feet should be checked daily for redness, blisters, calluses, cracks, or ulceration.

Patients who cannot inspect their own feet require assistance from caregivers.

Cast-Related Heel Pain

A patient in a cast who develops new heel pain should have the cast removed or opened sufficiently to permit direct skin inspection.

Persistent pain should never simply be attributed to the fracture without checking for pressure injury.

Superficial Pressure Injuries

Stage I and many Stage II lesions can often be treated successfully with:

Complete off-loading, protective padding, local wound care, and correction of underlying risk factors.

Deep Ulcers

Stage III and IV lesions often require more aggressive treatment.

This may include serial debridement, specialized dressings, negative-pressure wound therapy in selected cases, treatment of infection, and reconstruction or amputation when tissue destruction is extensive.

Antibiotics

Antibiotics are indicated when there is clinical infection, not merely because an ulcer is present.

Infected heel ulcers may be polymicrobial, especially in patients with diabetes or chronic wounds.

Empiric therapy may therefore require broad coverage initially, followed by adjustment according to culture results and clinical response.

Nursing Care

Nursing staff play a central role in prevention and early recognition.

Essential measures include:

Frequent repositioning, heel off-loading, skin inspection, moisture control, documentation of wounds, and prompt communication of new pressure injuries to the medical team.

Physical Therapy

Physical therapists can help with positioning, pressure relief, transfers, mobility, gait training, and selection of off-loading strategies.

Whirlpool Therapy

Whirlpool therapy was historically used for wound cleansing and debridement.

Modern wound care more commonly favors targeted debridement and moisture-controlled dressings because prolonged soaking may macerate tissue or increase contamination risk.

Nutrition

Adequate caloric and protein intake is important for wound healing.

A nutrition consultation should be considered in patients with weight loss, frailty, low intake, or laboratory evidence suggesting malnutrition.

Surgery

Debridement

Necrotic and infected tissue should be removed when indicated.

Limited soft-tissue debridement may occasionally be performed in a clinic or outpatient setting.

Operative Debridement

Extensive necrosis, deep infection, exposed bone, or suspected osteomyelitis may require formal operative debridement.

Bone Resection

Infected or nonviable calcaneal bone may need to be excised in severe cases.

Amputation

When infection, tissue necrosis, or ischemia cannot be controlled, partial or major amputation may be necessary.

This is generally reserved for advanced limb-threatening disease.

Referral

Patients with complicated heel ulcers may require coordinated care involving:

Orthopaedic surgery, wound-care specialists, vascular surgery, infectious disease, endocrinology, nursing, rehabilitation, and nutrition services.

Prognosis

Stage I and II

Superficial ulcers generally have a favorable prognosis when pressure is removed promptly and underlying risk factors are controlled.

Stage III and IV

Deep ulcers have a poorer prognosis because of the increased likelihood of infection, osteomyelitis, poor healing, and need for surgery.

Factors Affecting Outcome

Prognosis depends on:

Ulcer depth, vascular status, diabetes control, nutritional status, age, mobility, presence of neuropathy, and whether deep infection is present.

Complications

Osteomyelitis

Deep heel ulcers may extend into the calcaneus and cause chronic osteomyelitis.

Septic Arthritis

Spread into adjacent joints may result in septic arthritis.

Cellulitis and Abscess

Local infection may progress into surrounding soft tissues.

Systemic Infection

Severe infected ulcers can cause bacteremia or sepsis, particularly in medically frail patients.

Patient Monitoring

Heel pressure injuries require close and repeated reassessment because progression can occur rapidly when pressure persists.

Monitoring should include:

Wound size and depth, skin color, drainage, surrounding cellulitis, presence of necrotic tissue, vascular status, sensation, pain, nutritional status, and effectiveness of pressure relief.

Any evidence of worsening tissue destruction, systemic infection, exposed bone, or impaired perfusion warrants prompt escalation of treatment.

Orthopaedic Surgery - Heel Pain (Plantar Fasciitis)

Basics

Plantar fasciitis is the most common cause of plantar heel pain in adults.

Although commonly called “fasciitis,” the underlying process is predominantly degenerative rather than inflammatory, and the term plantar fasciopathy may more accurately describe the pathology.

Other Causes of Plantar Heel Pain

Not all plantar heel pain is caused by plantar fasciitis.

Important alternative causes include:

Entrapment of the first branch of the lateral plantar nerve, heel-pad atrophy, inflammatory enthesopathy associated with seronegative spondyloarthropathies, tarsal tunnel syndrome, and calcaneal stress fracture.

The first branch of the lateral plantar nerve is also commonly referred to as Baxter’s nerve.

Geriatric Considerations

In older adults, plantar heel pain may result from atrophy of the calcaneal fat pad, degenerative changes at the plantar fascial origin, or both.

Loss of heel cushioning can produce pain directly beneath the calcaneus during standing and walking.

Pediatric Considerations

Heel pain in children is more commonly caused by calcaneal apophysitis, or Sever disease, rather than plantar fasciitis.

Sever disease is related to repetitive traction and loading at the immature calcaneal apophysis, particularly around the Achilles tendon insertion.

Treatment of Sever Disease

Management typically includes:

Relative rest, activity modification, heel-cord stretching, NSAIDs when appropriate, heel cushioning, and temporary restriction from running or jumping sports.

A walking boot or short period of immobilization may be used for severe symptoms.

The disorder is self-limited and resolves after closure of the calcaneal apophysis with skeletal maturity.

Pregnancy Considerations

Heel pain during pregnancy may result from plantar fasciopathy or enthesopathy related to increased mechanical loading, weight gain, and hormonal changes.

Fluid retention may also contribute to compression neuropathies such as tarsal tunnel syndrome or entrapment of Baxter’s nerve.

Symptoms frequently improve after pregnancy.

Prevention

Plantar fasciitis cannot always be prevented, but risk may be reduced by avoiding:

Excessive weight gain, prolonged standing, poorly supportive footwear, and abrupt increases in running, jumping, or other repetitive impact activities.

Gradual progression of exercise and maintenance of calf flexibility may also be helpful.

Epidemiology

Plantar fasciitis is extremely common in adults.

It occurs most frequently during the third through fifth decades of life, although it can affect patients of virtually any adult age.

Risk Factors

Recognized risk factors include:

Restricted ankle dorsiflexion, tight gastrocnemius or Achilles complex, obesity or body mass index greater than 30, prolonged standing, running, jumping sports, diabetes mellitus, thyroid dysfunction, and inflammatory rheumatologic disease.

Etiology and Pathophysiology

The term “plantar fasciitis” suggests inflammation, but chronic cases usually show degenerative changes without substantial histologic inflammation.

Repeated tensile loading at the plantar fascia origin can result in microscopic injury, collagen degeneration, and chronic pain.

Repetitive Microtrauma

The plantar fascia is repeatedly tensioned during standing, walking, and running.

Overuse may produce microscopic tearing near its calcaneal origin.

Repeated loading before adequate healing can lead to chronic degeneration.

Contracture

A tight plantar fascia or heel cord increases tension across the plantar-medial calcaneal origin and may contribute to symptoms.

Associated Conditions

Frequently associated findings include:

Pes planus, cavus foot, Achilles or gastrocnemius contracture, obesity, and inflammatory arthropathies.

Flatfoot

Pes planus can increase tensile load on the plantar fascia by allowing greater elongation of the medial longitudinal arch.

Cavus Foot

A cavus foot may also predispose to plantar heel pain because the plantar fascia and other plantar soft tissues can become relatively tight.

Diagnosis

Plantar fasciitis is usually diagnosed clinically on the basis of a characteristic history and physical examination.

Imaging is not routinely required in a typical presentation.

History

The classic complaint is pain at the plantar-medial heel that is most severe with the first few steps in the morning.

A similar pattern may occur after prolonged sitting or inactivity.

Start-Up Pain

Pain often improves after several minutes of walking as the plantar fascia and surrounding tissues “loosen.”

Later-Day Symptoms

Although symptoms may improve initially with activity, pain can worsen again after prolonged standing, walking, or exercise later in the day.

Character of Pain

Patients may describe the discomfort as:

Aching, soreness, burning, stabbing, or sharp pain.

Physical Examination

Foot Alignment

The examiner should evaluate the foot for pes planus, cavus alignment, hindfoot deformity, and abnormal loading patterns.

Ankle Dorsiflexion

Ankle dorsiflexion should be measured with the knee both flexed and extended.

This helps distinguish isolated gastrocnemius tightness from a combined gastrocnemius-Achilles contracture.

Plantar Fascia Palpation

The most characteristic finding is focal tenderness at the plantar-medial calcaneal tubercle, where the plantar fascia originates.

Toe Dorsiflexion

Passive dorsiflexion of the toes tensions the plantar fascia through the windlass mechanism.

This maneuver may increase tenderness and reproduce the patient’s pain.

Neurologic Examination

The tarsal tunnel and course of the first branch of the lateral plantar nerve should be examined when neuropathic pain is suspected.

Tinel Sign

Percussion over the tarsal tunnel may reproduce tingling or burning into the plantar foot in patients with tibial nerve compression.

Baxter Nerve Entrapment

Tenderness or neuropathic pain deep to the abductor hallucis region may suggest entrapment of the first branch of the lateral plantar nerve.

Heel-Pad Atrophy

Pain centered directly beneath the calcaneal tuberosity rather than along the plantar-medial origin of the fascia may suggest fat-pad atrophy.

The heel pad may feel thin or poorly cushioned.

Calcaneal Stress Fracture

Medial-lateral compression of the calcaneus may reproduce pain in a calcaneal stress fracture.

This finding should prompt further investigation when symptoms are atypical for plantar fasciitis.

Laboratory Tests

Laboratory studies are not routinely required.

They may be considered in chronic, bilateral, recurrent, or atypical cases when systemic disease is suspected.

Potential Studies

Depending on the clinical setting, testing may include:

Rheumatoid factor, antinuclear antibodies, thyroid function studies, fasting glucose, hemoglobin A1C, inflammatory markers, and HLA-B27 testing.

HLA-B27 testing is most relevant when a seronegative spondyloarthropathy is suspected.

Imaging

Plain Radiographs

Weight-bearing radiographs of the foot may be obtained when pain is persistent, atypical, or associated with deformity.

They can help exclude fracture, arthritis, or other structural abnormalities.

Heel Spur

A plantar calcaneal spur is not diagnostic of plantar fasciitis.

Heel spurs are frequently found in asymptomatic individuals.

Their presence therefore does not establish the cause of heel pain.

Bone Scintigraphy

Bone scintigraphy may demonstrate increased uptake near the plantar fascia origin.

More diffuse calcaneal uptake may suggest a stress fracture.

Today, MRI is generally more useful when further imaging is needed.

MRI

MRI can demonstrate thickening and degenerative change of the proximal plantar fascia, with surrounding soft-tissue or adjacent calcaneal marrow edema.

Calcaneal Stress Fracture

A stress fracture generally produces more extensive bone marrow edema and may reveal a distinct fracture line.

Pathological Findings

Chronic plantar fasciitis demonstrates degenerative collagen changes at the plantar fascial origin.

Substantial chronic inflammatory cell infiltration is typically absent.

Differential Diagnosis

Important alternative diagnoses include:

Calcaneal apophysitis in children, calcaneal stress fracture, heel-pad atrophy, tarsal tunnel syndrome, Baxter nerve entrapment, inflammatory enthesopathy, and spinal radiculopathy.

Treatment

General Principles

Nonoperative treatment is the foundation of management.

Surgery is rarely required because the vast majority of patients improve with conservative measures.

Stretching

Stretching of the gastrocnemius-Achilles complex and plantar fascia should be performed regularly.

Stretching can be performed several times daily and before or after athletic activity.

Activity Modification

Activities that aggravate symptoms should be reduced temporarily.

Running, jumping, prolonged standing, and repetitive impact activity may need to be modified during the symptomatic phase.

Footwear and Heel Cushioning

A soft gel heel cup or cushioned heel insert may improve comfort by reducing impact at the plantar heel.

Supportive footwear is preferable to poorly cushioned or worn-out shoes.

Orthotic Arch Support

An arch support may be useful, particularly in patients with pes planus or excessive pronation.

Prefabricated devices are often sufficient initially.

Night Splints

A dorsiflexion night splint may help chronic symptoms by maintaining the ankle and plantar fascia in a gently stretched position overnight.

This may reduce severe first-step morning pain.

Ice and Massage

Ice application and deep-tissue or plantar fascial massage may provide symptomatic relief.

Rolling the plantar foot over a chilled bottle or similar device combines stretching, massage, and cooling.

Immobilization

A walking boot or short period of cast immobilization can be used for severe or recalcitrant symptoms to reduce repetitive loading of the plantar fascia.

Corticosteroid Injection

Local corticosteroid injection may be considered for persistent symptoms that have not responded to other nonoperative measures.

However, injections should be used cautiously because they carry risks including plantar fascial rupture and fat-pad atrophy.

Repeated injections are generally avoided.

Post-Injection Protection

Temporary restriction of high-impact activity after injection is appropriate.

A short period of protected weight bearing or boot use may be considered in selected patients.

Return to Activity

Once symptoms improve, activity should be resumed gradually.

Running and jumping should not be restarted abruptly at full intensity because sudden increases in repetitive stress can provoke recurrence.

Extracorporeal Shock-Wave Therapy

Extracorporeal shock-wave therapy can be considered for chronic plantar fasciitis that persists despite prolonged conservative treatment.

It may offer an alternative before operative intervention in appropriately selected patients.

Calcaneal Stress Fracture

Calcaneal stress fractures are generally treated with:

Activity restriction, protected weight bearing, NSAIDs or other analgesia when appropriate, and temporary immobilization when symptoms are severe.

Sever Disease

Treatment of calcaneal apophysitis similarly emphasizes:

Relative rest, heel-cord stretching, activity modification, heel cushioning, and short-term immobilization for severe cases.

Surgery is not indicated.

Heel-Pad Atrophy

Heel-pad atrophy is managed primarily with well-cushioned footwear, shock-absorbing heel cups, and reduction of repetitive impact loading.

Physical Therapy

Physical therapy can help teach proper calf and plantar fascia stretching, gait mechanics, strengthening, and graded return to activity.

It is particularly useful when tightness or biomechanical abnormalities contribute to symptoms.

Medication

NSAIDs may be used for short-term relief when pain is substantial.

Because the condition is largely degenerative rather than inflammatory, medication primarily provides symptomatic benefit rather than correcting the underlying pathology.

Surgery

Surgery is rarely indicated and is generally reserved for patients with persistent disabling symptoms despite at least 6–9 months of well-performed nonoperative treatment.

Partial Plantar Fascia Release

The usual procedure consists of partial release of the plantar fascia origin.

A complete release should be avoided because it may destabilize the longitudinal arch.

Heel-Spur Removal

Routine removal of a calcaneal spur is generally unnecessary because the spur itself is often not the source of pain.

Nerve Decompression

When persistent tarsal tunnel syndrome or entrapment of Baxter’s nerve contributes to symptoms, decompression may be performed in selected cases, sometimes in combination with partial plantar fascia release.

Contraindication in Sever Disease

Plantar fascia surgery is not appropriate for calcaneal apophysitis.

Sever disease is a self-limited developmental condition.

Follow-Up

Prognosis

The prognosis is excellent.

More than 90% of patients improve with nonoperative treatment and are able to return to normal activities.

Resolution may nevertheless require several months.

Complications

Plantar Fascia Rupture

Plantar fascial rupture may occur after corticosteroid injection or excessive surgical release.

Arch Collapse

Excessive release of the plantar fascia can weaken support of the medial longitudinal arch and contribute to arch collapse.

Lateral Column Overload

Loss of plantar fascial tension may shift mechanical stress toward the lateral midfoot, producing painful lateral column overload.

Fat-Pad Atrophy

Corticosteroid injection may contribute to degeneration or thinning of the heel fat pad, producing persistent plantar heel pain.

Patient Monitoring

Follow-up should assess pain intensity, morning first-step symptoms, tenderness at the plantar fascial origin, ankle dorsiflexion, activity tolerance, and adherence to stretching and footwear modification.

Persistent atypical pain, neurologic symptoms, focal bony tenderness, or failure to improve should prompt reconsideration of the diagnosis and evaluation for alternative causes such as stress fracture, nerve entrapment, or inflammatory disease.

Medicine – Causes of Hypernatraemia

Hypernatraemia is an elevation of the serum sodium concentration, usually defined as:

Serum Na⁺ >145 mmol/L.

The most important concept is that hypernatraemia is usually a disorder of water balance rather than simply an excess of sodium. In most patients, the problem is:

Too little water relative to total-body sodium and potassium.

Therefore, the major mechanisms are:

Free-water loss.

Inadequate water intake/replacement.

Excess sodium administration.

Hypernatraemia produces hypertonicity, causing water to move out of cells. The brain is particularly vulnerable to this cellular dehydration.

1. Basic Mechanism

Serum sodium concentration rises when:

Water loss > sodium loss

or when:

Sodium gain > water gain.

Therefore:

FREE-WATER DEFICIT → ↑ SERUM Na⁺.

This is why hypernatraemia is particularly common when a patient cannot respond normally to thirst.

2. Role of Thirst

An intact thirst mechanism is an extremely powerful defence against hypernatraemia.

When plasma osmolality rises:

Hypothalamic osmoreceptors stimulated

↓

Thirst increases

• ●

ADH secretion increases

↓

Patient drinks water

• ●

Kidneys conserve water

↓

Serum osmolality moves toward normal.

Therefore persistent severe hypernatraemia usually develops when there is:

Impaired access to water

or

Water loss so large that intake cannot compensate.

3. High-Risk Patients

Hypernatraemia is particularly likely in patients who cannot independently obtain water.

Examples include:

Infants.

Frail older adults.

Unconscious patients.

Intubated patients.

Patients with neurological impairment.

Patients dependent on others for fluid intake.

Therefore hypernatraemia in hospitalised or dependent patients should always prompt careful assessment of:

Fluid intake and ongoing losses.

4. Major Classification

The causes can be organised into:

Water loss.

Sodium gain.

Water loss through osmotic diuresis.

Diabetes insipidus.

This is more useful than memorising individual diseases without understanding their mechanisms.

5. Water Loss Without Adequate Replacement

The original notes correctly identify:

Fluid loss without water replacement

as a major cause.

Water can be lost through:

Skin.

Respiratory tract.

Gastrointestinal tract.

Kidneys.

If the lost water is not adequately replaced, serum sodium rises.

6. Insensible Water Loss

Water is continuously lost through:

Skin

and

Respiration.

These are called:

Insensible losses.

Normally they are replaced by drinking water.

However, insensible losses increase substantially with:

Fever.

Tachypnoea.

High environmental temperature.

Mechanical ventilation in some circumstances.

If replacement is inadequate:

Free-water deficit → hypernatraemia.

7. Burns

The original notes correctly include:

Burns.

Extensive burns damage the normal skin barrier and can cause substantial:

Water and electrolyte loss.

Increased evaporative water loss from damaged skin can contribute to:

Hypernatraemia, particularly if replacement does not adequately match free-water losses.

However, the exact sodium abnormality depends on the composition of losses and replacement fluids.

8. Vomiting

The original notes include:

Vomiting.

Vomiting causes loss of both:

Water

and

Electrolytes.

Hypernatraemia can occur when the water deficit becomes proportionally greater and the patient cannot replace the lost water.

Therefore:

VOMITING + POOR WATER INTAKE → POSSIBLE HYPERNATRAEMIC DEHYDRATION.

However, vomiting does not automatically cause hypernatraemia; depending on replacement and physiology, sodium may be normal or low.

9. Diarrhoea

An important additional gastrointestinal cause is:

Diarrhoea.

Severe watery diarrhoea can cause substantial water loss.

If:

Water loss exceeds sodium loss

and replacement is inadequate:

Hypernatraemia develops.

This is particularly important in:

Infants and dependent older adults.

10. Excessive Sweating

Profuse sweating can also produce hypernatraemia.

Sweat is generally:

Hypotonic relative to plasma.

Therefore the body loses proportionally more water than sodium.

With prolonged sweating and inadequate water replacement:

Serum sodium rises.

11. Sodium Gain

Hypernatraemia can also occur because of:

Excessive sodium administration.

This is less common than water-loss hypernatraemia but is particularly relevant in:

Hospital settings.

12. Excessive Saline Administration

The original notes state:

“Excessive fluid replacement with saline.”

This requires some qualification.

Hypernatraemia is most likely when a patient receives excessive amounts of:

Hypertonic sodium-containing fluid, such as hypertonic saline.

Large sodium loads can raise extracellular sodium concentration, particularly if renal sodium excretion is impaired or insufficient water is available.

13. Normal Saline – Important Clarification

Ordinary:

0.9% sodium chloride

contains approximately:

154 mmol/L of sodium.

It is isotonic saline and is not usually a major direct cause of severe hypernatraemia when appropriately administered.

The more classic iatrogenic sodium-loading causes are:

Hypertonic saline.

Excess sodium bicarbonate.

Incorrectly prepared/high-sodium feeds or solutions.

Therefore the original phrase “excessive saline” is better remembered as:

EXCESSIVE HYPERTONIC SODIUM ADMINISTRATION.

14. Sodium Bicarbonate

Large amounts of:

Sodium bicarbonate

can provide a substantial sodium load.

Therefore excessive administration can contribute to:

Hypernatraemia.

This is another important example of:

Sodium-gain hypernatraemia.

15. Hyperosmolar Hyperglycaemic State

The original term:

Hyperosmolar non-ketotic state – HONK

is now more commonly called:

Hyperosmolar hyperglycaemic state – HHS.

HHS is characterised by:

Severe hyperglycaemia.

Marked hyperosmolality.

Profound dehydration.

Usually relatively little ketoacidosis compared with DKA, although overlap can occur.

16. Why HHS Causes Severe Water Loss

Very high blood glucose exceeds the renal threshold.

↓

Glucose enters urine.

↓

Glucose acts as an osmotic agent.

↓

Osmotic diuresis.

↓

Large urinary losses of:

Water + sodium + potassium.

However, the water deficit can become proportionally very large.

Therefore:

HHS → PROFOUND FREE-WATER DEFICIT.

17. Sodium in HHS Can Be Misleading

Early in severe hyperglycaemia, extracellular glucose draws water:

Out of cells.

This may initially lower the measured sodium through:

Translocational dilution.

However, ongoing osmotic diuresis causes enormous free-water losses.

Therefore the measured sodium may become:

Normal or high, and the corrected sodium may reveal substantial hypernatraemia even when the initial measured sodium is not elevated.

18. Diabetes Insipidus

The original notes correctly identify:

Diabetes insipidus – DI

as one of the most important causes of hypernatraemia.

DI causes inability to conserve free water.

There are two major forms:

Central DI.

Nephrogenic DI.

19. Central Diabetes Insipidus

Central DI results from:

Insufficient ADH/vasopressin secretion.

Therefore:

↓ ADH

↓

↓ Collecting-duct water reabsorption

↓

Large quantities of:

Dilute urine

↓

Free-water loss

↓

Hypernatraemia if water intake cannot keep pace.

20. Causes of Central DI

Important causes include:

Pituitary/hypothalamic surgery.

Head trauma.

Craniopharyngioma and other hypothalamic/pituitary lesions.

Sarcoidosis.

Langerhans cell histiocytosis.

Idiopathic/autoimmune disease.

Genetic disorders such as Wolfram syndrome.

21. Nephrogenic Diabetes Insipidus

In nephrogenic DI:

ADH is present

but:

The kidney does not respond adequately.

Therefore the collecting ducts cannot appropriately conserve water.

The result is:

Large-volume dilute urine → free-water loss → possible hypernatraemia.

22. Causes of Nephrogenic DI

Important causes include:

Lithium.

Hypercalcaemia.

Hypokalaemia.

Chronic renal tubular/interstitial disease.

Inherited AVPR2 or AQP2 abnormalities.

For examination purposes:

LITHIUM = CLASSIC ACQUIRED NEPHROGENIC DI CAUSE.

23. Why DI Does Not Always Cause Hypernatraemia

This is an important clinical point.

A patient with DI and an intact thirst mechanism may drink enough water to replace urinary losses.

Therefore:

DI does not automatically mean hypernatraemia.

Hypernatraemia develops particularly when:

Water intake cannot match urinary water loss.

This is especially dangerous in unconscious, confused or dependent patients.

24. Conn Syndrome

The original notes include:

Conn syndrome – primary hyperaldosteronism.

Aldosterone promotes:

Na⁺ reabsorption

and

K⁺ and H⁺ secretion.

Therefore primary aldosteronism classically produces:

Hypertension.

Hypokalaemia.

Metabolic alkalosis.

25. Does Conn Syndrome Usually Cause Hypernatraemia?

This requires an important correction.

Despite increased sodium reabsorption:

Clinically significant hypernatraemia is NOT a typical feature of primary hyperaldosteronism.

Why?

Initial sodium retention causes extracellular volume expansion.

↓

This suppresses proximal sodium reabsorption and promotes:

Pressure natriuresis.

↓

Other natriuretic mechanisms increase sodium excretion.

↓

A new sodium balance is established.

This phenomenon is sometimes called:

Aldosterone escape.

Therefore serum sodium usually remains:

Normal or only minimally increased.

26. High-Yield Conn Pattern

For examinations, Conn syndrome is much better remembered as:

HYPERTENSION + HYPOKALAEMIA + METABOLIC ALKALOSIS.

With:

↑ Aldosterone

and

↓ Renin.

Do not rely on hypernatraemia as a major diagnostic feature.

27. Renal Water Loss

Besides DI and HHS, other renal processes can cause excessive water loss.

These include:

Osmotic diuresis.

Post-obstructive diuresis.

Recovery phase of AKI.

Certain diuretics in appropriate circumstances.

If water replacement is inadequate, these conditions may produce:

Hypernatraemia.

28. Osmotic Diuresis

An osmotic substance within the renal tubules retains water in the tubular lumen.

This increases urine output.

Important examples include:

Glucose in uncontrolled diabetes mellitus.

Mannitol.

Therefore:

OSMOTIC DIURESIS → ↑ URINARY WATER LOSS → POSSIBLE HYPERNATRAEMIA.

29. Post-Obstructive Diuresis

After relief of significant urinary obstruction, some patients develop:

Marked polyuria.

The kidneys may temporarily have impaired concentrating ability and excrete large quantities of water and electrolytes.

Without adequate replacement:

Dehydration + hypernatraemia

can develop.

30. Clinical Features of Hypernatraemia

Symptoms largely result from:

Hypertonicity and cellular dehydration.

The brain is especially affected.

Patients may develop:

Intense thirst.

Weakness.

Irritability.

Lethargy.

Confusion.

Neuromuscular hyperexcitability.

31. Severe Hypernatraemia

Severe or rapidly developing hypernatraemia can cause:

Marked neurological dysfunction.

Seizures.

Reduced consciousness.

Coma.

In severe acute cases, brain-cell shrinkage can contribute to:

Intracranial vascular injury or haemorrhage.

32. Chronic Adaptation

When hypernatraemia develops gradually, brain cells adapt by accumulating intracellular osmolytes.

This reduces cellular water loss and limits brain shrinkage.

However, this adaptation creates an important treatment issue:

Chronic hypernatraemia should generally be corrected carefully rather than abruptly.

33. Investigation

The first questions should be:

Is the patient losing water?

Can the patient access water?

Is urine appropriately concentrated?

Has the patient received excessive sodium?

Useful investigations include:

Serum sodium.

Serum glucose.

Renal function.

Serum and urine osmolality.

Urine volume.

Urinary electrolytes when appropriate.

34. Urine Osmolality

Urine osmolality is particularly useful.

If a hypernatraemic patient has:

Very concentrated urine,

the kidneys are appropriately conserving water.

This suggests water loss from elsewhere or inadequate intake, such as:

GI loss, skin loss or impaired access to water.

If the patient has:

Inappropriately dilute urine despite hypernatraemia,

the kidneys are failing to conserve water.

Think particularly about:

Diabetes insipidus.

35. Hypernatraemia With Polyuria

A particularly useful clinical pattern is:

Hypernatraemia + polyuria.

Think:

Diabetes insipidus.

Osmotic diuresis from hyperglycaemia.

Post-obstructive diuresis.

Recovery phase of AKI.

Urine osmolality and glucose help distinguish these mechanisms.

36. Hypernatraemia With Low Urine Volume

If the patient has hypernatraemia but the kidneys are producing a small amount of concentrated urine, think more about:

Extrarenal water loss

or

Inadequate water intake.

Examples include:

Fever.

Sweating.

Burns.

Diarrhoea.

Vomiting with inadequate replacement.

37. Treatment Principles

The fundamental treatment is:

Replace the water deficit

and

Treat the underlying cause.

However, treatment must take into account:

Circulatory status.

Severity.

Duration of hypernatraemia.

Ongoing water losses.

38. Hypovolaemic Hypernatraemia

If the patient has severe intravascular volume depletion or shock, the immediate priority is restoration of:

Circulating volume.

Isotonic crystalloid may initially be required for haemodynamic resuscitation.

Once circulation is stabilised, the remaining:

Free-water deficit

can be corrected with an appropriate hypotonic strategy.

39. Free-Water Replacement

Depending on the clinical situation, free water may be replaced:

Orally.

Enterally.

or using appropriate:

Intravenous hypotonic fluid.

The exact strategy depends on the patient’s clinical condition and electrolyte status.

40. Treatment of Central DI

Central DI is generally treated with:

Desmopressin – DDAVP

when appropriate.

Desmopressin replaces the deficient antidiuretic effect.

Therefore:

DESMOPRESSIN → ↑ COLLECTING-DUCT WATER REABSORPTION → ↓ URINE OUTPUT.

41. Treatment of Nephrogenic DI

Treatment involves correcting the underlying cause where possible.

Examples include:

Correct hypercalcaemia.

Correct hypokalaemia.

Review lithium therapy.

Ensure adequate water replacement.

Selected patients may benefit from:

Thiazide therapy, and amiloride is particularly useful in lithium-associated nephrogenic DI.

42. Avoid Over-Rapid Correction

In chronic hypernatraemia, rapid reduction of extracellular osmolality can cause water to move rapidly into adapted brain cells.

This creates a risk of:

Cerebral oedema.

Therefore chronic or duration-unknown hypernatraemia is generally corrected:

Gradually with careful monitoring.

43. Causes of Hypernatraemia – Note Form

INADEQUATE WATER REPLACEMENT / EXTRARENAL WATER LOSS:

Burns.

Fever.

Sweating.

Tachypnoea.

Vomiting.

Diarrhoea.

Inability to access water.

RENAL WATER LOSS:

Central diabetes insipidus.

Nephrogenic diabetes insipidus.

Osmotic diuresis.

Post-obstructive diuresis.

Recovery phase of AKI.

HYPERGLYCAEMIC OSMOTIC DIURESIS:

Hyperosmolar hyperglycaemic state – HHS.

Severe uncontrolled diabetes.

SODIUM GAIN:

Hypertonic saline.

Excess sodium bicarbonate.

Excessive high-sodium solutions/feeds.

44. Important Corrections to the Original Notes

The original:

“HONK”

is better called:

HYPEROSMOLAR HYPERGLYCAEMIC STATE – HHS.

HHS causes profound dehydration through:

Glucose-induced osmotic diuresis.

The original:

“Excessive fluid replacement with saline”

is more accurately remembered as:

EXCESSIVE SODIUM ADMINISTRATION, PARTICULARLY HYPERTONIC SALINE OR OTHER LARGE SODIUM LOADS.

The original:

“Conn syndrome”

requires qualification.

Primary hyperaldosteronism causes sodium retention, but persistent clinically significant hypernatraemia is unusual because of aldosterone escape and intact thirst/water regulation.

Remember Conn syndrome primarily as:

HYPERTENSION + HYPOKALAEMIA + METABOLIC ALKALOSIS.

The original:

“Fluid loss without water replacement”

is the most important general principle.

Hypernatraemia most commonly reflects:

WATER DEFICIT RELATIVE TO SODIUM.

Key Clinical Pattern

For rapid recall:

HYPERNATRAEMIA = THINK TOO LITTLE WATER FIRST.

WATER LOSS:

BURNS + FEVER + SWEATING + VOMITING + DIARRHOEA.

↓

No adequate water replacement

↓

HYPERNATRAEMIA.

POLYURIA + HYPERNATRAEMIA:

Think:

DIABETES INSIPIDUS

or

OSMOTIC DIURESIS.

HHS:

SEVERE HYPERGLYCAEMIA → GLYCOSURIA → OSMOTIC DIURESIS → MASSIVE WATER LOSS.

SODIUM GAIN:

Think:

HYPERTONIC SALINE / EXCESS SODIUM BICARBONATE.

CONN SYNDROME:

Do not primarily think hypernatraemia.

Think:

HYPERTENSION + ↓ K⁺ + METABOLIC ALKALOSIS + ↑ ALDOSTERONE + ↓ RENIN.

And the central principle is:

HYPONATRAEMIA IS USUALLY RELATIVE WATER EXCESS.

HYPERNATRAEMIA IS USUALLY RELATIVE WATER DEFICIT.

Medicine – Causes of Hyponatraemia

Hyponatraemia is a reduction in the serum sodium concentration, usually defined as:

Serum Na⁺ <135 mmol/L.

An important principle is that hyponatraemia is usually a disorder of water balance relative to sodium, rather than simply a lack of sodium in the body. In many cases, there is too much water relative to the amount of exchangeable sodium and potassium.

A useful clinical approach is to first determine whether the hyponatraemia is truly hypotonic, and then assess the patient’s extracellular fluid volume status.

1. Modern Classification of Hyponatraemia

Hyponatraemia is best approached as:

Hypovolaemic hyponatraemia – patient is volume depleted/dehydrated.

Euvolaemic hyponatraemia – no obvious volume depletion or oedema.

Hypervolaemic hyponatraemia – excess total body water with oedema/volume expansion.

There are also:

Non-hypotonic forms of hyponatraemia, including hyperglycaemia-related hyponatraemia and true laboratory pseudohyponatraemia.

This is more precise than simply dividing patients into:

“dehydrated” versus “well hydrated.”

2. Why Serum Sodium Falls

Serum sodium concentration reflects the relationship between:

Body sodium/potassium

and

Body water.

Therefore serum sodium can fall because:

Sodium is lost and replaced with relatively more water.

or

Excess water is retained.

or

Water shifts from cells into extracellular fluid.

or, occasionally,

A laboratory measurement artefact produces pseudohyponatraemia.

3. Hypovolaemic Hyponatraemia

In hypovolaemic hyponatraemia, the patient has lost both:

Sodium

and

Water.

However, sodium loss is proportionally greater, or the losses are subsequently replaced with relatively hypotonic fluid.

The resulting reduction in effective circulating volume stimulates:

ADH secretion.

ADH then promotes water retention, which further lowers serum sodium.

4. Clinical Features of Hypovolaemia

Depending on severity, the patient may have:

Thirst.

Dry mucous membranes.

Reduced skin turgor.

Postural hypotension.

Tachycardia.

Reduced jugular venous pressure.

Oliguria.

Severe volume depletion may progress to:

Hypotension and circulatory shock.

5. Diuretic Excess

The original notes correctly identify:

Diuretic excess

as an important cause of hypovolaemic hyponatraemia.

The most important drug association is:

Thiazide diuretics.

Thiazides impair urinary dilution while causing renal sodium loss.

Therefore:

THIAZIDE → Na⁺ LOSS + IMPAIRED FREE-WATER EXCRETION → HYPONATRAEMIA.

6. Thiazides Versus Loop Diuretics

Although both can cause volume and electrolyte depletion, clinically significant hyponatraemia is particularly associated with:

Thiazides.

Loop diuretics can also contribute, but they interfere with the renal medullary concentration gradient and are generally less characteristically associated with severe hyponatraemia than thiazides.

7. Gastrointestinal Loss

The original notes correctly include:

Vomiting

and

Diarrhoea.

Both can produce:

Extrarenal sodium and water loss.

The resulting hypovolaemia stimulates:

ADH.

If the patient drinks water or receives relatively hypotonic replacement fluid:

Serum sodium can fall further.

8. Vomiting

Persistent vomiting causes loss of:

Hydrogen ions.

Chloride.

Sodium and water.

Volume depletion activates:

RAAS + ADH.

Therefore vomiting can produce:

Hypovolaemic hyponatraemia.

It is also characteristically associated with:

Hypokalaemic metabolic alkalosis.

9. Diarrhoea

Severe diarrhoea causes substantial loss of:

Water.

Sodium.

Potassium.

Bicarbonate.

Therefore a patient may develop:

Hypovolaemia + hyponatraemia + hypokalaemia + normal-anion-gap metabolic acidosis.

10. Addison Disease

The original notes correctly identify:

Addison disease – primary adrenal insufficiency.

This is an important endocrine cause of hyponatraemia.

Primary adrenal insufficiency produces deficiencies of:

Cortisol

and

Aldosterone.

11. Why Addison Disease Causes Hyponatraemia

Aldosterone deficiency causes:

Renal sodium loss.

↓

Volume depletion.

↓

Cortisol deficiency also increases:

ADH secretion.

↓

Water retention.

↓

Hyponatraemia.

Because aldosterone normally promotes potassium excretion, primary adrenal insufficiency may also cause:

Hyperkalaemia.

Therefore:

HYPONATRAEMIA + HYPERKALAEMIA + HYPOTENSION → THINK PRIMARY ADRENAL INSUFFICIENCY.

12. Renal Sodium Loss

The original notes include:

Renal failure – diuretic phase.

A better modern description is that renal sodium loss can occur during certain phases of:

Recovering acute kidney injury, particularly when urine output increases before tubular reabsorptive function has fully recovered.

This can produce:

Polyuria + sodium loss + potassium loss + volume depletion.

However, kidney disease can cause hyponatraemia through several different mechanisms, so it should not automatically be classified as hypovolaemic.

13. Other Renal Causes of Hypovolaemic Hyponatraemia

Other causes of renal sodium wasting include:

Salt-wasting nephropathies.

Mineralocorticoid deficiency.

Cerebral salt wasting in selected neurological patients.

The key clue is:

Volume depletion despite inappropriate urinary sodium loss.

14. Hyperglycaemia – Important Correction

The original notes describe DKA as:

“Pseudo-hyponatraemia because glucose is very high.”

This requires an important correction.

Hyperglycaemia usually causes:

Hypertonic/translocational hyponatraemia, not true laboratory pseudohyponatraemia.

15. Why Hyperglycaemia Lowers Sodium

When extracellular glucose becomes markedly elevated:

Extracellular osmolality rises.

↓

Water moves:

From intracellular → extracellular fluid.

↓

Extracellular water dilutes sodium.

↓

Measured serum sodium falls.

Therefore:

HYPERGLYCAEMIA → WATER SHIFTS OUT OF CELLS → DILUTION OF SERUM Na⁺.

This is particularly relevant in:

DKA

and

Hyperosmolar hyperglycaemic state – HHS.

16. Corrected Sodium in Hyperglycaemia

Because hyperglycaemia lowers the measured sodium through water redistribution, clinicians may estimate a:

Corrected serum sodium.

The exact correction varies with glucose concentration and formula used, but the central concept is:

The measured Na⁺ underestimates what the sodium would be after glucose is normalised.

Therefore DKA-associated low sodium should not simply be labelled:

Pseudohyponatraemia.

17. Euvolaemic Hyponatraemia

In euvolaemic hyponatraemia, there is:

No obvious clinical dehydration

and

No major peripheral oedema.

The most important cause is:

SIADH.

Other causes include:

Adrenal insufficiency.

Severe hypothyroidism in appropriate settings.

Primary polydipsia/water excess.

Low-solute intake.

18. SIADH

The original notes correctly identify:

Syndrome of inappropriate antidiuretic hormone secretion – SIADH

as a major cause of euvolaemic hyponatraemia.

In SIADH:

Inappropriate ADH effect

↓

↑ Renal water reabsorption

↓

Water retained disproportionately to sodium

↓

Dilutional hyponatraemia.

19. Typical SIADH Pattern

The characteristic pattern is:

↓ Serum Na⁺.

↓ Serum osmolality.

Inappropriately concentrated urine.

Urine osmolality usually >100 mOsm/kg.

Urinary sodium often >30 mmol/L when intake and renal function are appropriate.

Clinical euvolaemia.

Before diagnosing SIADH, important mimics such as:

Adrenal insufficiency

should be excluded.

20. Hypothyroidism

The original notes include:

Hypothyroidism.

Severe hypothyroidism can impair free-water excretion and contribute to:

Hyponatraemia.

However, mild or uncomplicated hypothyroidism is a much less common explanation for significant hyponatraemia than older teaching sometimes implies.

The association is strongest with:

Severe hypothyroidism/myxoedema.

21. Water Overload

Excessive water intake can overwhelm the kidneys’ ability to excrete free water.

This may occur with:

Primary polydipsia.

Psychogenic polydipsia.

Excessive hypotonic fluid administration.

If water intake exceeds maximal renal excretory capacity:

Plasma becomes diluted

↓

Hyponatraemia develops.

22. Primary Polydipsia

Primary polydipsia is particularly associated with:

Very high water intake.

Unlike SIADH, ADH is appropriately suppressed.

Therefore the urine is generally:

Very dilute.

This distinction is useful:

SIADH → urine inappropriately concentrated.

Primary polydipsia → urine appropriately very dilute.

23. Alcohol Excess – Important Clarification

The original notes include:

Alcohol excess.

Alcohol itself does not provide one single mechanism for hyponatraemia.

An important alcohol-associated condition is:

Low-solute intake, classically called beer potomania.

24. Beer Potomania

Patients consuming large quantities of beer while eating very little may have extremely low dietary:

Protein

and

Salt/solute.

The kidneys require solute to excrete water efficiently.

Therefore:

Very low solute intake + substantial fluid intake

↓

Limited renal free-water excretion

↓

Hyponatraemia.

A similar mechanism can occur with other forms of severe low-solute nutrition.

25. Hypervolaemic Hyponatraemia

Several conditions listed under the original heading:

“Patient well hydrated”

are actually better classified as:

Hypervolaemic hyponatraemia.

These include:

Congestive heart failure.

Liver cirrhosis.

Nephrotic syndrome.

Advanced kidney failure.

These patients have increased total-body water and often increased total-body sodium, but:

Water retention exceeds sodium retention.

26. Congestive Heart Failure

The original notes correctly identify:

Congestive cardiac failure – heart failure.

In significant heart failure, cardiac output and effective arterial blood volume fall.

The kidneys interpret this as inadequate perfusion despite the patient having excess total body fluid.

This activates:

RAAS.

Sympathetic nervous system.

ADH.

27. Why Heart Failure Causes Hyponatraemia

↓ Effective arterial blood volume

↓

↑ ADH

↓

↑ Free-water retention

↓

Water retention exceeds sodium retention

↓

Dilutional hyponatraemia.

Therefore patients may simultaneously have:

Peripheral oedema + pulmonary congestion + hyponatraemia.

28. Liver Cirrhosis

The original notes correctly include:

Liver cirrhosis.

Advanced cirrhosis causes:

Splanchnic vasodilatation

and reduced effective arterial blood volume.

This activates:

RAAS + sympathetic activity + ADH.

The result is:

Sodium retention + even greater water retention.

Therefore:

CIRRHOSIS → ASCITES/OEDEMA + DILUTIONAL HYPONATRAEMIA.

29. Nephrotic Syndrome

The original notes correctly include:

Nephrotic syndrome.

Severe nephrotic syndrome causes:

Heavy proteinuria

↓

Hypoalbuminaemia

↓

Altered effective circulating volume in some patients

↓

Neurohormonal sodium/water retention

↓

Oedema.

If water retention is excessive relative to sodium, hyponatraemia can develop.

30. Kidney Failure

Kidney failure can produce hyponatraemia because the kidneys may lose the ability to:

Excrete free water effectively.

If water intake exceeds renal excretory capacity:

Water accumulates

↓

Dilutional hyponatraemia.

Therefore advanced kidney failure commonly belongs conceptually to the:

Hypervolaemic or impaired-water-excretion group, rather than simply the “dehydrated” group.

31. Hypoalbuminaemia – Important Clarification

The original notes list:

Hypoalbuminaemia

as a cause.

Hypoalbuminaemia itself does not automatically produce hyponatraemia.

Rather, disorders associated with severe hypoalbuminaemia—such as:

Cirrhosis

or

Nephrotic syndrome

may produce reduced effective circulating volume and neurohormonal water retention.

Therefore it is better to identify the:

Underlying disease and volume status

rather than treating hypoalbuminaemia itself as a stand-alone major mechanism.

32. Pseudohyponatraemia

True:

Pseudohyponatraemia

is a laboratory measurement artefact.

It can occur when the non-aqueous fraction of plasma becomes markedly increased, particularly with extreme:

Hyperlipidaemia

or

Hyperproteinaemia.

33. Hyperlipidaemia

The original notes correctly associate severe:

Hyperlipidaemia

with pseudohyponatraemia.

Marked lipid elevation reduces the proportion of the plasma sample composed of water.

Certain laboratory methods using:

Indirect ion-selective electrodes

can then report a falsely low sodium concentration.

34. Pseudohyponatraemia and Plasma Osmolality

Because the actual sodium concentration in the plasma water is normal:

Plasma tonicity is not reduced by the pseudohyponatraemia itself.

Therefore:

PSEUDOHYPONATRAEMIA = LOW REPORTED Na⁺ WITHOUT TRUE HYPOTONICITY.

Modern direct ion-selective electrode measurements, such as those commonly used in blood-gas analysers, are not affected in the same way.

35. Hyperproteinaemia

Another classic cause of true pseudohyponatraemia is severe:

Hyperproteinaemia.

This can occur in conditions such as:

Paraproteinaemia, for example selected plasma-cell disorders.

Therefore:

Extreme lipids/proteins + low Na⁺ + normal measured tonicity → consider pseudohyponatraemia.

36. Hyperglycaemia Versus Pseudohyponatraemia

This distinction is particularly important:

HYPERGLYCAEMIA

causes:

Hypertonic/translocational hyponatraemia.

The sodium is genuinely diluted by movement of water into extracellular fluid.

SEVERE HYPERLIPIDAEMIA/HYPERPROTEINAEMIA

can cause:

Laboratory pseudohyponatraemia

with certain measurement techniques.

Therefore:

DKA ≠ classic pseudohyponatraemia.

37. Symptoms of Hyponatraemia

Symptoms depend strongly on:

Severity

and especially:

Speed of development.

Mild or slowly developing hyponatraemia may cause:

Nausea.

Headache.

Fatigue.

Difficulty concentrating.

Gait disturbance.

Confusion.

38. Severe Acute Hyponatraemia

A rapid fall in sodium causes water to enter brain cells.

This can produce:

Cerebral oedema.

Severe manifestations include:

Vomiting.

Marked confusion.

Seizures.

Reduced consciousness.

Coma.

Therefore:

ACUTE SEVERE SYMPTOMATIC HYPONATRAEMIA IS A MEDICAL EMERGENCY.

39. Initial Investigation

When hyponatraemia is discovered, the first important questions are:

Is it truly hypotonic?

What is the patient’s volume status?

Is ADH appropriately suppressed or active?

Useful investigations include:

Serum osmolality.

Urine osmolality.

Urinary sodium.

Glucose.

Renal function.

Potassium.

Further endocrine testing may include adrenal and thyroid assessment when indicated.

40. Step 1 – Check Serum Osmolality

Low serum osmolality

suggests:

True hypotonic hyponatraemia.

High serum osmolality

with hyponatraemia suggests an effective extracellular osmole, classically:

Severe hyperglycaemia.

A low reported sodium without corresponding hypotonicity may suggest:

Pseudohyponatraemia, depending on the clinical and laboratory context.

41. Step 2 – Check Urine Osmolality

If urine is:

Very dilute, around ≤100 mOsm/kg,

ADH is largely suppressed.

Think particularly about:

Primary polydipsia

or

Very low solute intake.

If urine is:

>100 mOsm/kg,

ADH is active.

The next step is to determine:

Why ADH is active.

42. Step 3 – Assess Volume Status and Urinary Sodium

In hypovolaemia, ADH secretion is physiologically appropriate because the body is attempting to preserve circulating volume.

Urinary sodium can then help distinguish:

Extrarenal sodium loss

from

Renal sodium loss.

For example:

Diarrhoea → kidneys generally conserve sodium.

Whereas:

Diuretics/mineralocorticoid deficiency → urinary sodium loss may persist.

Interpretation can be complicated by recent diuretic use and kidney disease.

43. Hypovolaemic Hyponatraemia – Note Form

GI LOSS:

Vomiting.

Diarrhoea.

RENAL LOSS:

Thiazide diuretics – particularly important.

Other diuretics.

Salt-wasting renal disease.

Recovering AKI with excessive urinary losses.

ENDOCRINE:

Primary adrenal insufficiency – Addison disease.

Think:

Low Na⁺ + high K⁺ + hypotension.

44. Euvolaemic Hyponatraemia – Note Form

SIADH – major cause.

Adrenal insufficiency.

Severe hypothyroidism.

Primary polydipsia/water excess.

Low-solute intake, including beer potomania.

45. Hypervolaemic Hyponatraemia – Note Form

HEART FAILURE:

Reduced effective arterial volume

↓

ADH activation

↓

Water retention

↓

Hyponatraemia + oedema/congestion.

LIVER CIRRHOSIS:

Splanchnic vasodilatation

↓

Reduced effective arterial volume

↓

ADH + RAAS activation

↓

Ascites/oedema + hyponatraemia.

NEPHROTIC SYNDROME:

Heavy proteinuria + oedema physiology

↓

Sodium/water retention

↓

Possible dilutional hyponatraemia.

ADVANCED KIDNEY FAILURE:

Impaired free-water excretion

↓

Water accumulation

↓

Dilutional hyponatraemia.

46. Non-Hypotonic Hyponatraemia – Note Form

HYPERGLYCAEMIA:

High extracellular glucose

↓

Water shifts out of cells

↓

Serum sodium diluted

↓

Hypertonic/translocational hyponatraemia.

This is not classic pseudohyponatraemia.

SEVERE HYPERLIPIDAEMIA:

Laboratory measurement artefact with susceptible methods

↓

Pseudohyponatraemia.

SEVERE HYPERPROTEINAEMIA:

Laboratory measurement artefact

↓

Pseudohyponatraemia.

47. Treatment Principles

Treatment depends completely on:

The cause.

Volume status.

Severity of symptoms.

Duration of hyponatraemia.

A patient with hypovolaemic hyponatraemia requires a different strategy from someone with SIADH or heart failure.

48. Hypovolaemic Hyponatraemia Treatment

The underlying sodium and volume deficit generally needs correction, often using:

Isotonic saline

when clinically appropriate.

Restoration of effective circulating volume suppresses the non-osmotic ADH stimulus, allowing the kidneys to excrete excess water.

The underlying cause must also be treated.

49. SIADH Treatment

Depending on severity and context, treatment may include:

Fluid restriction

and treatment of the underlying cause.

Selected persistent cases may require other specialist therapies.

50. Severe Symptomatic Hyponatraemia

Patients with severe neurological manifestations such as:

Seizures or markedly impaired consciousness

may require carefully controlled:

Hypertonic saline.

Serum sodium must be monitored closely.

51. Danger of Rapid Correction

Overly rapid correction of chronic hyponatraemia can cause:

Osmotic demyelination syndrome – ODS.

Therefore:

CHRONIC HYPONATRAEMIA MUST NOT BE CORRECTED TOO RAPIDLY.

The risk is particularly important in patients with severe chronic hyponatraemia, malnutrition, alcohol-related disease, liver disease or hypokalaemia.

52. Important Corrections to the Original Notes

The original division into:

“Patient dehydrated”

and

“Patient well hydrated”

is useful as a starting point, but the more accurate classification is:

HYPOVOLAEMIC + EUVOLAEMIC + HYPERVOLAEMIC HYPONATRAEMIA.

Heart failure, cirrhosis and nephrotic syndrome should not simply be described as “well hydrated.”

These patients are typically:

Hypervolaemic, often with oedema or ascites, while their effective arterial circulating volume is reduced.

The original statement:

“DKA = pseudohyponatraemia because glucose is very high”

should be corrected to:

DKA/HYPERGLYCAEMIA → HYPERTONIC TRANSLOCATIONAL HYPONATRAEMIA.

True laboratory:

Pseudohyponatraemia

is classically associated with extreme:

Hyperlipidaemia

or

Hyperproteinaemia

when susceptible laboratory measurement methods are used.

Hypoalbuminaemia alone should not be memorised as a major independent cause. Think instead of the underlying disease, such as:

Cirrhosis or nephrotic syndrome.

Key Clinical Pattern

For rapid recall, approach hyponatraemia according to tonicity first, then volume status.

LOW Na⁺ + LOW SERUM OSMOLALITY = TRUE HYPOTONIC HYPONATRAEMIA.

HYPOVOLAEMIC:

Think:

DIURETICS + VOMITING + DIARRHOEA + ADDISON DISEASE.

EUVOLAEMIC:

Think:

SIADH + ADRENAL INSUFFICIENCY + SEVERE HYPOTHYROIDISM + PRIMARY POLYDIPSIA + LOW-SOLUTE INTAKE.

HYPERVOLAEMIC:

Think:

HEART FAILURE + CIRRHOSIS + NEPHROTIC SYNDROME + ADVANCED KIDNEY FAILURE.

HIGH GLUCOSE + LOW Na⁺:

Think:

HYPERTONIC/TRANSLOCATIONAL HYPONATRAEMIA.

EXTREME LIPIDS OR PROTEINS + LOW REPORTED Na⁺ WITHOUT TRUE HYPOTONICITY:

Think:

PSEUDOHYPONATRAEMIA.

And the most important safety principle is:

SEVERE NEUROLOGICAL SYMPTOMS → URGENT TREATMENT, BUT CHRONIC HYPONATRAEMIA MUST BE CORRECTED CAREFULLY TO AVOID OSMOTIC DEMYELINATION.

Medicine – Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Syndrome of inappropriate antidiuretic hormone secretion – SIADH is a disorder in which antidiuretic hormone (ADH), also called arginine vasopressin (AVP), continues to act despite low plasma osmolality.

The inappropriate ADH effect causes excessive renal water reabsorption, producing:

Water retention → dilutional hyponatraemia → low plasma osmolality → inappropriately concentrated urine.

Importantly, the major abnormality is water excess rather than primary sodium deficiency.

1. Normal ADH Physiology

ADH is synthesised in the:

Supraoptic and paraventricular nuclei of the hypothalamus.

It is transported to the:

Posterior pituitary,

where it is stored and released.

ADH acts primarily on V₂ receptors in collecting-duct principal cells, increasing insertion of:

Aquaporin-2 water channels.

Therefore:

ADH → V₂ receptors → aquaporin-2 insertion → ↑ renal water reabsorption.

2. What Happens in SIADH?

Normally, falling plasma osmolality should suppress ADH secretion.

In SIADH, ADH secretion or action persists despite:

Hypo-osmolality.

Therefore:

Inappropriate ADH activity

↓

↑ Collecting-duct water reabsorption

↓

Water retained disproportionately to sodium

↓

Dilutional hyponatraemia

↓

↓ Plasma osmolality.

3. Why the Urine Remains Concentrated

When plasma osmolality is low, the normal kidney should produce:

Very dilute urine.

In SIADH, ADH continues to act on the collecting ducts.

Therefore the urine remains:

Inappropriately concentrated.

A typical biochemical pattern is:

↓ Serum Na⁺

↓ Serum osmolality

Urine osmolality >100 mOsm/kg rather than maximally dilute

Urinary sodium often >30 mmol/L when salt intake and renal function are adequate.

4. Volume Status in SIADH

Patients with SIADH are usually clinically:

Euvolaemic.

Although ADH initially causes water retention, the resulting mild extracellular-volume expansion promotes:

Natriuresis – urinary sodium loss.

Consequently, obvious peripheral oedema is generally absent.

Therefore the classic pattern is:

EUVOLEMIC HYPOTONIC HYPONATRAEMIA.

5. Major Causes of SIADH

The causes can be organised into four major groups:

Malignancy.

Pulmonary disease.

Central nervous system disease.

Drugs.

Other causes include postoperative states, pain and nausea.

6. Malignancy

Malignancy is an important cause because certain tumours can produce:

Ectopic ADH.

The classic association is:

Small-cell lung carcinoma – SCLC.

7. Small-Cell Lung Carcinoma

The most important malignancy to remember is:

SMALL-CELL LUNG CARCINOMA.

SCLC is a neuroendocrine tumour capable of ectopic hormone production.

It can produce:

ADH

↓

Water retention

↓

Dilutional hyponatraemia

↓

SIADH.

Therefore:

SMALL-CELL LUNG CANCER + HYPONATRAEMIA → THINK SIADH.

8. Other Malignancies

The original notes also include:

Mesothelioma.

Bladder malignancy.

Prostate malignancy.

Pancreatic malignancy.

Lymphoma.

SIADH has been reported with several malignant diseases, but these associations are considerably less characteristic than:

Small-cell lung carcinoma.

For examination purposes, SCLC should remain the major malignancy association.

9. Pulmonary Disorders

Pulmonary disease can stimulate inappropriate ADH secretion even without ectopic production by a tumour.

Important pulmonary causes include:

Pneumonia.

Pulmonary tuberculosis.

Lung abscess.

Other significant pulmonary illnesses can also precipitate SIADH.

10. Pneumonia

The original notes correctly identify:

Pneumonia

as an important cause.

Pulmonary infection, inflammation, hypoxaemia, physiological stress and associated nausea/pain may stimulate:

ADH release.

Therefore pneumonia can produce:

Hyponatraemia due to SIADH.

11. Pulmonary Tuberculosis

The original notes correctly include:

Tuberculosis – TB.

Pulmonary TB can be associated with inappropriate ADH secretion.

However, when a patient with TB has hyponatraemia, other causes may also need consideration, including:

Adrenal insufficiency

if the adrenal glands are involved.

This matters because adrenal insufficiency can mimic the biochemical appearance of SIADH.

12. Lung Abscess

A:

Lung abscess

may also stimulate inappropriate ADH release as part of severe pulmonary infection.

Therefore:

PULMONARY INFECTION → ADH STIMULATION → POSSIBLE SIADH.

13. Central Nervous System Disorders

Many CNS disorders can disrupt the normal hypothalamic regulation of:

ADH secretion.

The original notes include:

Encephalitis.

Meningitis.

Trauma.

Subarachnoid haemorrhage.

Guillain–Barré syndrome.

Hydrocephalus.

Acute intermittent porphyria.

14. Meningitis and Encephalitis

Inflammation or infection involving the CNS can disturb hypothalamic ADH regulation.

Therefore:

Meningitis

and

Encephalitis

may cause inappropriate ADH release.

The resulting hyponatraemia can worsen neurological symptoms if severe.

15. Head Trauma

The original notes correctly include:

Trauma.

Head injury can disrupt hypothalamic and pituitary regulation.

Interestingly, depending on the nature of the injury, trauma can produce either:

SIADH

or

Central diabetes insipidus.

Therefore careful monitoring of:

Serum sodium and urine output

is important after significant neurological injury.

16. Subarachnoid Haemorrhage

The original notes correctly include:

Subarachnoid haemorrhage – SAH.

SAH is an important neurological setting in which:

Hyponatraemia

may develop.

SIADH is one possible mechanism.

17. SIADH Versus Cerebral Salt Wasting

Hyponatraemia following neurological injury is not automatically SIADH.

A differential diagnosis is:

Cerebral salt wasting.

The key conceptual distinction is:

SIADH → usually clinically euvolaemic.

Cerebral salt wasting → renal sodium loss with hypovolaemia.

Distinguishing them is important because their management differs.

18. Guillain–Barré Syndrome

The original notes correctly include:

Guillain–Barré syndrome – GBS.

GBS can be associated with SIADH, particularly in more severe disease.

Autonomic and neuroendocrine disturbances may contribute to:

Inappropriate ADH secretion.

Therefore significant hyponatraemia can occur during GBS.

19. Hydrocephalus

Hydrocephalus may disturb hypothalamic function or intracranial pressure relationships and can occasionally be associated with:

SIADH.

This is less common than some of the classic CNS causes but remains recognised.

20. Acute Intermittent Porphyria

The original notes correctly include:

Acute intermittent porphyria – AIP.

AIP can produce:

Severe abdominal pain.

Neurological symptoms.

Autonomic disturbance.

Psychiatric manifestations.

and importantly:

Hyponatraemia.

SIADH is an important mechanism contributing to hyponatraemia during an acute attack.

Therefore:

ABDOMINAL PAIN + NEUROPSYCHIATRIC FEATURES + HYPONATRAEMIA → CONSIDER AIP.

21. Drug-Induced SIADH

Medications are an important cause of SIADH and should always be reviewed in a patient with unexplained:

Euvolaemic hyponatraemia.

The original notes include:

Tricyclic antidepressants.

Carbamazepine.

Chlorpropamide.

Phenothiazines.

Several additional modern drug associations are also important.

22. Antidepressants

The original notes correctly include:

Tricyclic antidepressants – TCAs.

However, an especially important modern association is:

Selective serotonin reuptake inhibitors – SSRIs.

Examples include:

Sertraline.

Fluoxetine.

Citalopram.

SSRIs can cause SIADH and hyponatraemia, particularly in:

Older adults and other susceptible patients.

23. Carbamazepine

The original notes correctly identify:

Carbamazepine.

Carbamazepine can enhance the renal effects of ADH and/or promote inappropriate antidiuretic activity.

Therefore:

CARBAMAZEPINE → WATER RETENTION → HYPONATRAEMIA.

The related antiseizure drug:

Oxcarbazepine

is also strongly associated with hyponatraemia.

24. Chlorpropamide

The original notes include:

Chlorpropamide.

Chlorpropamide is an older sulfonylurea that can:

Potentiate the renal action of ADH.

It was historically well recognised as a cause of:

Hyponatraemia/SIADH-like antidiuresis.

Its importance has decreased because chlorpropamide is now used much less frequently.

25. Phenothiazines

The original notes correctly include:

Phenothiazines.

These drugs can promote inappropriate antidiuretic activity and contribute to:

Hyponatraemia.

Medication history is therefore particularly important in patients taking:

Psychotropic drugs.

26. Other Important Drug Causes

Additional medications associated with SIADH or inappropriate antidiuresis include:

SSRIs.

SNRIs.

Oxcarbazepine.

Some antipsychotic drugs.

Cyclophosphamide.

Vincristine.

Desmopressin and other vasopressin-related therapies, which can cause water retention through direct antidiuretic effects.

Drug-induced hyponatraemia may also involve mechanisms other than classic SIADH, so the clinical context remains important.

27. Pain, Nausea and Surgery

An important addition to the original list is:

Pain.

Nausea.

Surgery/postoperative stress.

These are potent non-osmotic stimuli for:

ADH release.

Therefore hospitalised postoperative patients may develop transient:

Hyponatraemia due to increased ADH activity.

28. Symptoms of SIADH

The symptoms are mainly caused by:

Hyponatraemia

and the resulting movement of water into brain cells.

The severity depends on both:

How low the sodium falls

and

How rapidly it falls.

29. Mild or Moderate Hyponatraemia

Patients may develop:

Nausea.

Headache.

Fatigue.

Dizziness.

Difficulty concentrating.

Confusion.

Some patients with chronic mild hyponatraemia may have relatively subtle symptoms.

30. Severe Acute Hyponatraemia

Rapidly developing severe hyponatraemia can produce:

Cerebral oedema.

This may cause:

Vomiting.

Marked confusion.

Seizures.

Reduced consciousness.

Coma.

Therefore:

SEVERE SYMPTOMATIC HYPONATRAEMIA IS A MEDICAL EMERGENCY.

31. Diagnostic Pattern of SIADH

The characteristic laboratory pattern is:

Hyponatraemia.

↓

Low measured serum osmolality.

↓

Urine remains:

Inappropriately concentrated.

↓

Urinary sodium is generally:

Not appropriately suppressed.

↓

Patient appears:

Clinically euvolaemic.

32. SIADH Is a Diagnosis of Exclusion

This is extremely important.

A patient should not be diagnosed with SIADH simply because they have:

Low sodium + concentrated urine.

Other causes of hypotonic hyponatraemia must be excluded.

Particularly important are:

Adrenal insufficiency.

Hypothyroidism when clinically relevant.

Renal failure.

Diuretic-related hyponatraemia.

Hypovolaemia.

Heart failure/cirrhosis and other oedematous states.

33. Adrenal Insufficiency

Adrenal insufficiency is particularly important because cortisol deficiency increases:

ADH secretion.

Therefore adrenal insufficiency may closely resemble SIADH.

Primary adrenal insufficiency may additionally cause:

Hyperkalaemia

because of aldosterone deficiency.

Therefore:

HYPONATRAEMIA SHOULD NOT AUTOMATICALLY BE LABELLED SIADH WITHOUT CONSIDERING ADRENAL INSUFFICIENCY.

34. Serum Osmolality

True SIADH produces:

Hypotonic hyponatraemia.

Therefore:

Serum osmolality is low.

This helps distinguish it from situations in which serum sodium is low but plasma tonicity is not truly reduced.

35. Urine Osmolality

In appropriate physiological suppression of ADH, hypotonic plasma should cause the kidneys to produce:

Maximally dilute urine.

In SIADH, this does not happen.

Therefore:

Urine osmolality is >100 mOsm/kg in typical diagnostic criteria.

The key concept is:

The urine is too concentrated for the low plasma osmolality.

36. Urinary Sodium

In SIADH, urinary sodium is often:

>30 mmol/L

when dietary sodium intake is adequate and there is no confounding renal dysfunction or diuretic use.

This occurs because the patient is not truly sodium-depleted and mild volume expansion promotes:

Natriuresis.

37. Treatment Principles

Management depends on:

Severity of hyponatraemia.

Presence of neurological symptoms.

How rapidly the sodium fell.

Underlying cause.

Treatment must be cautious because excessively rapid correction of chronic hyponatraemia can cause severe neurological injury.

38. Treat the Underlying Cause

Whenever possible:

Treat pneumonia or other infection.

Treat the underlying malignancy.

Review and stop the causative medication when appropriate.

Treat CNS disease.

Correcting the underlying cause may allow normal ADH regulation to return.

39. Fluid Restriction

For many patients with chronic or mild-to-moderate SIADH, a major initial strategy is:

Fluid restriction.

This reduces further free-water accumulation.

The effectiveness depends on the severity of SIADH and the patient’s urinary electrolyte and osmolality profile.

40. Severe Symptomatic Hyponatraemia

Patients with severe neurological symptoms such as:

Seizures.

Marked reduced consciousness.

or other manifestations of severe acute hyponatraemia may require carefully controlled:

Hypertonic saline.

This should be performed with close monitoring of serum sodium.

41. Avoid Over-Rapid Sodium Correction

An important complication of excessively rapid correction of chronic hyponatraemia is:

Osmotic demyelination syndrome – ODS.

Therefore:

Serum sodium must be corrected in a controlled manner.

Patients at particularly high risk of ODS include those with profound chronic hyponatraemia, malnutrition, alcohol-related disease, liver disease and hypokalaemia.

42. Other Treatment Options

Selected patients with persistent SIADH may require additional approaches such as:

Increased solute intake or oral urea.

Loop diuretics in selected circumstances.

Vasopressin receptor antagonists – vaptans – in carefully selected patients.

These treatments require clinical judgement and monitoring.

43. Demeclocycline

As discussed with nephrogenic diabetes insipidus:

Demeclocycline

reduces renal responsiveness to ADH.

Therefore it can induce:

Nephrogenic DI

and was historically used to counteract SIADH.

Its use is now limited in many settings because of:

Nephrotoxicity and other disadvantages.

44. Causes of SIADH – Note Form

MALIGNANCY:

Small-cell lung carcinoma – classic and most important.

Mesothelioma and several other malignancies have been reported.

Bladder/prostate/pancreatic malignancies and lymphoma are less classic associations.

PULMONARY:

Pneumonia.

Tuberculosis.

Lung abscess.

Other severe pulmonary disease.

CNS:

Meningitis.

Encephalitis.

Head trauma.

Subarachnoid haemorrhage.

Guillain–Barré syndrome.

Hydrocephalus.

Acute intermittent porphyria.

DRUGS:

SSRIs/SNRIs.

Tricyclic antidepressants.

Carbamazepine.

Oxcarbazepine.

Phenothiazines/other selected antipsychotics.

Chlorpropamide – historical.

Cyclophosphamide.

Vincristine.

OTHER STIMULI:

Pain.

Nausea.

Postoperative stress.

45. Diagnostic Pattern – Note Form

Serum sodium:

↓.

Serum osmolality:

↓.

Urine osmolality:

Inappropriately ↑ relative to plasma.

Usually >100 mOsm/kg rather than maximally dilute.

Urinary sodium:

Often >30 mmol/L when intake and renal function are appropriate.

Clinical volume status:

Usually euvolaemic.

Renal function:

Should not explain the water-handling abnormality.

Adrenal insufficiency:

Must be excluded.

Thyroid disease:

Consider/exclude where appropriate.

46. SIADH Versus Diabetes Insipidus – Copyable Comparison

SIADH

ADH effect:

Too much/inappropriately persistent.

↓

Kidney retains:

Water.

↓

Urine volume:

Reduced or relatively low.

↓

Urine:

Inappropriately concentrated.

↓

Serum sodium:

Low.

↓

Serum osmolality:

Low.

DI

ADH effect:

Too little ADH in central DI

or

Kidney resistant to ADH in nephrogenic DI.

↓

Kidney loses:

Free water.

↓

Urine volume:

High.

↓

Urine:

Very dilute.

↓

Serum sodium:

May become high if water intake is insufficient.

↓

Serum osmolality:

May become high.

47. Important Clarifications to the Original Notes

The most important malignant cause to remember is:

SMALL-CELL LUNG CARCINOMA → ECTOPIC ADH → SIADH.

Other malignancies can be associated, but they are less characteristic.

For pulmonary disease, remember:

PNEUMONIA + TB + LUNG ABSCESS.

For CNS disease, remember:

MENINGITIS/ENCEPHALITIS + SAH + TRAUMA + GBS.

For medications, the original list remains useful, but modern high-yield additions include:

SSRIs and oxcarbazepine.

Chlorpropamide is now largely a:

Historical association because the drug is rarely used.

Most importantly:

SIADH IS A DIAGNOSIS OF EXCLUSION.

Low sodium alone does not diagnose SIADH.

Key Clinical Pattern

For rapid recall:

SIADH = INAPPROPRIATELY HIGH ADH EFFECT → WATER RETENTION → DILUTIONAL HYPONATRAEMIA.

Think:

SCLC → CLASSIC MALIGNANCY.

PNEUMONIA / TB → PULMONARY.

MENINGITIS / ENCEPHALITIS / SAH / TRAUMA → CNS.

SSRI / CARBAMAZEPINE / OXCARBAZEPINE → DRUGS.

The characteristic biochemical pattern is:

↓ SERUM Na⁺

• ●

↓ SERUM OSMOLALITY

• ●

INAPPROPRIATELY CONCENTRATED URINE

• ●

URINARY Na⁺ NOT SUPPRESSED

• ●

CLINICAL EUVOLAEMIA.

And remember the opposite patterns:

SIADH → TOO MUCH ADH EFFECT → WATER RETAINED → LOW Na⁺.

DI → TOO LITTLE ADH EFFECT → WATER LOST → HIGH-VOLUME DILUTE URINE ± HIGH Na⁺.

1. Normal ADH Physiology ADH is synthesised in the: Supraoptic and paraventricular nuclei of the hypothalamus. It is transported to the: Posterior pituitary, where it is stored and released. ADH acts primarily on V₂ receptors in collecting-duct principal cells, increasing insertion of: Aquaporin-2 water channels. Therefore: ADH → V₂ receptors → aquaporin-2 insertion → ↑ renal water reabsorption.

2. What Happens in SIADH? Normally, falling plasma osmolality should suppress ADH secretion. In SIADH, ADH secretion or action persists despite: Hypo-osmolality. Therefore: Inappropriate ADH activity ↓ ↑ Collecting-duct water reabsorption ↓ Water retained disproportionately to sodium ↓ Dilutional hyponatraemia ↓ ↓ Plasma osmolality.

3. Why the Urine Remains Concentrated When plasma osmolality is low, the normal kidney should produce: Very dilute urine. In SIADH, ADH continues to act on the collecting ducts. Therefore the urine remains: Inappropriately concentrated. A typical biochemical pattern is: ↓ Serum Na⁺ ↓ Serum osmolality Urine osmolality >100 mOsm/kg rather than maximally dilute Urinary sodium often >30 mmol/L when salt intake and renal function are adequate.

4. Volume Status in SIADH Patients with SIADH are usually clinically: Euvolaemic. Although ADH initially causes water retention, the resulting mild extracellular-volume expansion promotes: Natriuresis – urinary sodium loss. Consequently, obvious peripheral oedema is generally absent. Therefore the classic pattern is: EUVOLEMIC HYPOTONIC HYPONATRAEMIA.

5. Major Causes of SIADH The causes can be organised into four major groups: Malignancy. Pulmonary disease. Central nervous system disease. Drugs. Other causes include postoperative states, pain and nausea.

6. Malignancy Malignancy is an important cause because certain tumours can produce: Ectopic ADH. The classic association is: Small-cell lung carcinoma – SCLC.

7. Small-Cell Lung Carcinoma The most important malignancy to remember is: SMALL-CELL LUNG CARCINOMA. SCLC is a neuroendocrine tumour capable of ectopic hormone production. It can produce: ADH ↓ Water retention ↓ Dilutional hyponatraemia ↓ SIADH. Therefore: SMALL-CELL LUNG CANCER + HYPONATRAEMIA → THINK SIADH.

8. Other Malignancies The original notes also include: Mesothelioma. Bladder malignancy. Prostate malignancy. Pancreatic malignancy. Lymphoma. SIADH has been reported with several malignant diseases, but these associations are considerably less characteristic than: Small-cell lung carcinoma. For examination purposes, SCLC should remain the major malignancy association.

9. Pulmonary Disorders Pulmonary disease can stimulate inappropriate ADH secretion even without ectopic production by a tumour. Important pulmonary causes include: Pneumonia. Pulmonary tuberculosis. Lung abscess. Other significant pulmonary illnesses can also precipitate SIADH.

10. Pneumonia The original notes correctly identify: Pneumonia as an important cause. Pulmonary infection, inflammation, hypoxaemia, physiological stress and associated nausea/pain may stimulate: ADH release. Therefore pneumonia can produce: Hyponatraemia due to SIADH.

11. Pulmonary Tuberculosis The original notes correctly include: Tuberculosis – TB. Pulmonary TB can be associated with inappropriate ADH secretion. However, when a patient with TB has hyponatraemia, other causes may also need consideration, including: Adrenal insufficiency if the adrenal glands are involved. This matters because adrenal insufficiency can mimic the biochemical appearance of SIADH.

12. Lung Abscess A: Lung abscess may also stimulate inappropriate ADH release as part of severe pulmonary infection. Therefore: PULMONARY INFECTION → ADH STIMULATION → POSSIBLE SIADH.

13. Central Nervous System Disorders Many CNS disorders can disrupt the normal hypothalamic regulation of: ADH secretion. The original notes include: Encephalitis. Meningitis. Trauma. Subarachnoid haemorrhage. Guillain–Barré syndrome. Hydrocephalus. Acute intermittent porphyria.

14. Meningitis and Encephalitis Inflammation or infection involving the CNS can disturb hypothalamic ADH regulation. Therefore: Meningitis and Encephalitis may cause inappropriate ADH release. The resulting hyponatraemia can worsen neurological symptoms if severe.

15. Head Trauma The original notes correctly include: Trauma. Head injury can disrupt hypothalamic and pituitary regulation. Interestingly, depending on the nature of the injury, trauma can produce either: SIADH or Central diabetes insipidus. Therefore careful monitoring of: Serum sodium and urine output is important after significant neurological injury.

16. Subarachnoid Haemorrhage The original notes correctly include: Subarachnoid haemorrhage – SAH. SAH is an important neurological setting in which: Hyponatraemia may develop. SIADH is one possible mechanism.

17. SIADH Versus Cerebral Salt Wasting Hyponatraemia following neurological injury is not automatically SIADH. A differential diagnosis is: Cerebral salt wasting. The key conceptual distinction is: SIADH → usually clinically euvolaemic. Cerebral salt wasting → renal sodium loss with hypovolaemia. Distinguishing them is important because their management differs.

18. Guillain–Barré Syndrome The original notes correctly include: Guillain–Barré syndrome – GBS. GBS can be associated with SIADH, particularly in more severe disease. Autonomic and neuroendocrine disturbances may contribute to: Inappropriate ADH secretion. Therefore significant hyponatraemia can occur during GBS.

19. Hydrocephalus Hydrocephalus may disturb hypothalamic function or intracranial pressure relationships and can occasionally be associated with: SIADH. This is less common than some of the classic CNS causes but remains recognised.

20. Acute Intermittent Porphyria The original notes correctly include: Acute intermittent porphyria – AIP. AIP can produce: Severe abdominal pain. Neurological symptoms. Autonomic disturbance. Psychiatric manifestations. and importantly: Hyponatraemia. SIADH is an important mechanism contributing to hyponatraemia during an acute attack. Therefore: ABDOMINAL PAIN + NEUROPSYCHIATRIC FEATURES + HYPONATRAEMIA → CONSIDER AIP.

21. Drug-Induced SIADH Medications are an important cause of SIADH and should always be reviewed in a patient with unexplained: Euvolaemic hyponatraemia. The original notes include: Tricyclic antidepressants. Carbamazepine. Chlorpropamide. Phenothiazines. Several additional modern drug associations are also important.

22. Antidepressants The original notes correctly include: Tricyclic antidepressants – TCAs. However, an especially important modern association is: Selective serotonin reuptake inhibitors – SSRIs. Examples include: Sertraline. Fluoxetine. Citalopram. SSRIs can cause SIADH and hyponatraemia, particularly in: Older adults and other susceptible patients.

23. Carbamazepine The original notes correctly identify: Carbamazepine. Carbamazepine can enhance the renal effects of ADH and/or promote inappropriate antidiuretic activity. Therefore: CARBAMAZEPINE → WATER RETENTION → HYPONATRAEMIA. The related antiseizure drug: Oxcarbazepine is also strongly associated with hyponatraemia.

24. Chlorpropamide The original notes include: Chlorpropamide. Chlorpropamide is an older sulfonylurea that can: Potentiate the renal action of ADH. It was historically well recognised as a cause of: Hyponatraemia/SIADH-like antidiuresis. Its importance has decreased because chlorpropamide is now used much less frequently.

25. Phenothiazines The original notes correctly include: Phenothiazines. These drugs can promote inappropriate antidiuretic activity and contribute to: Hyponatraemia. Medication history is therefore particularly important in patients taking: Psychotropic drugs.

26. Other Important Drug Causes Additional medications associated with SIADH or inappropriate antidiuresis include: SSRIs. SNRIs. Oxcarbazepine. Some antipsychotic drugs. Cyclophosphamide. Vincristine. Desmopressin and other vasopressin-related therapies, which can cause water retention through direct antidiuretic effects. Drug-induced hyponatraemia may also involve mechanisms other than classic SIADH, so the clinical context remains important.

27. Pain, Nausea and Surgery An important addition to the original list is: Pain. Nausea. Surgery/postoperative stress. These are potent non-osmotic stimuli for: ADH release. Therefore hospitalised postoperative patients may develop transient: Hyponatraemia due to increased ADH activity.

28. Symptoms of SIADH The symptoms are mainly caused by: Hyponatraemia and the resulting movement of water into brain cells. The severity depends on both: How low the sodium falls and How rapidly it falls.

29. Mild or Moderate Hyponatraemia Patients may develop: Nausea. Headache. Fatigue. Dizziness. Difficulty concentrating. Confusion. Some patients with chronic mild hyponatraemia may have relatively subtle symptoms.

30. Severe Acute Hyponatraemia Rapidly developing severe hyponatraemia can produce: Cerebral oedema. This may cause: Vomiting. Marked confusion. Seizures. Reduced consciousness. Coma. Therefore: SEVERE SYMPTOMATIC HYPONATRAEMIA IS A MEDICAL EMERGENCY.

31. Diagnostic Pattern of SIADH The characteristic laboratory pattern is: Hyponatraemia. ↓ Low measured serum osmolality. ↓ Urine remains: Inappropriately concentrated. ↓ Urinary sodium is generally: Not appropriately suppressed. ↓ Patient appears: Clinically euvolaemic.

32. SIADH Is a Diagnosis of Exclusion This is extremely important. A patient should not be diagnosed with SIADH simply because they have: Low sodium + concentrated urine. Other causes of hypotonic hyponatraemia must be excluded. Particularly important are: Adrenal insufficiency. Hypothyroidism when clinically relevant. Renal failure. Diuretic-related hyponatraemia. Hypovolaemia. Heart failure/cirrhosis and other oedematous states.

33. Adrenal Insufficiency Adrenal insufficiency is particularly important because cortisol deficiency increases: ADH secretion. Therefore adrenal insufficiency may closely resemble SIADH. Primary adrenal insufficiency may additionally cause: Hyperkalaemia because of aldosterone deficiency. Therefore: HYPONATRAEMIA SHOULD NOT AUTOMATICALLY BE LABELLED SIADH WITHOUT CONSIDERING ADRENAL INSUFFICIENCY.

34. Serum Osmolality True SIADH produces: Hypotonic hyponatraemia. Therefore: Serum osmolality is low. This helps distinguish it from situations in which serum sodium is low but plasma tonicity is not truly reduced.

35. Urine Osmolality In appropriate physiological suppression of ADH, hypotonic plasma should cause the kidneys to produce: Maximally dilute urine. In SIADH, this does not happen. Therefore: Urine osmolality is >100 mOsm/kg in typical diagnostic criteria. The key concept is: The urine is too concentrated for the low plasma osmolality.

36. Urinary Sodium In SIADH, urinary sodium is often: >30 mmol/L when dietary sodium intake is adequate and there is no confounding renal dysfunction or diuretic use. This occurs because the patient is not truly sodium-depleted and mild volume expansion promotes: Natriuresis.

37. Treatment Principles Management depends on: Severity of hyponatraemia. Presence of neurological symptoms. How rapidly the sodium fell. Underlying cause. Treatment must be cautious because excessively rapid correction of chronic hyponatraemia can cause severe neurological injury.

38. Treat the Underlying Cause Whenever possible: Treat pneumonia or other infection. Treat the underlying malignancy. Review and stop the causative medication when appropriate. Treat CNS disease. Correcting the underlying cause may allow normal ADH regulation to return.

39. Fluid Restriction For many patients with chronic or mild-to-moderate SIADH, a major initial strategy is: Fluid restriction. This reduces further free-water accumulation. The effectiveness depends on the severity of SIADH and the patient’s urinary electrolyte and osmolality profile.

40. Severe Symptomatic Hyponatraemia Patients with severe neurological symptoms such as: Seizures. Marked reduced consciousness. or other manifestations of severe acute hyponatraemia may require carefully controlled: Hypertonic saline. This should be performed with close monitoring of serum sodium.

41. Avoid Over-Rapid Sodium Correction An important complication of excessively rapid correction of chronic hyponatraemia is: Osmotic demyelination syndrome – ODS. Therefore: Serum sodium must be corrected in a controlled manner. Patients at particularly high risk of ODS include those with profound chronic hyponatraemia, malnutrition, alcohol-related disease, liver disease and hypokalaemia.

42. Other Treatment Options Selected patients with persistent SIADH may require additional approaches such as: Increased solute intake or oral urea. Loop diuretics in selected circumstances. Vasopressin receptor antagonists – vaptans – in carefully selected patients. These treatments require clinical judgement and monitoring.

43. Demeclocycline As discussed with nephrogenic diabetes insipidus: Demeclocycline reduces renal responsiveness to ADH. Therefore it can induce: Nephrogenic DI and was historically used to counteract SIADH. Its use is now limited in many settings because of: Nephrotoxicity and other disadvantages.

44. Causes of SIADH – Note Form MALIGNANCY: Small-cell lung carcinoma – classic and most important. Mesothelioma and several other malignancies have been reported. Bladder/prostate/pancreatic malignancies and lymphoma are less classic associations.

PULMONARY: Pneumonia. Tuberculosis. Lung abscess. Other severe pulmonary disease.

CNS: Meningitis. Encephalitis. Head trauma. Subarachnoid haemorrhage. Guillain–Barré syndrome. Hydrocephalus. Acute intermittent porphyria.

DRUGS: SSRIs/SNRIs. Tricyclic antidepressants. Carbamazepine. Oxcarbazepine. Phenothiazines/other selected antipsychotics. Chlorpropamide – historical. Cyclophosphamide. Vincristine.

OTHER STIMULI: Pain. Nausea. Postoperative stress.

45. Diagnostic Pattern – Note Form Serum sodium: ↓.

Serum osmolality: ↓.

Urine osmolality: Inappropriately ↑ relative to plasma. Usually >100 mOsm/kg rather than maximally dilute.

Urinary sodium: Often >30 mmol/L when intake and renal function are appropriate.

Clinical volume status: Usually euvolaemic.

Renal function: Should not explain the water-handling abnormality.

Adrenal insufficiency: Must be excluded.

Thyroid disease: Consider/exclude where appropriate.

46. SIADH Versus Diabetes Insipidus – Copyable Comparison SIADH ADH effect: Too much/inappropriately persistent. ↓ Kidney retains: Water. ↓ Urine volume: Reduced or relatively low. ↓ Urine: Inappropriately concentrated. ↓ Serum sodium: Low. ↓ Serum osmolality: Low.

DI ADH effect: Too little ADH in central DI or Kidney resistant to ADH in nephrogenic DI. ↓ Kidney loses: Free water. ↓ Urine volume: High. ↓ Urine: Very dilute. ↓ Serum sodium: May become high if water intake is insufficient. ↓ Serum osmolality: May become high.

47. Important Clarifications to the Original Notes The most important malignant cause to remember is: SMALL-CELL LUNG CARCINOMA → ECTOPIC ADH → SIADH. Other malignancies can be associated, but they are less characteristic.

For pulmonary disease, remember: PNEUMONIA + TB + LUNG ABSCESS.

For CNS disease, remember: MENINGITIS/ENCEPHALITIS + SAH + TRAUMA + GBS.

For medications, the original list remains useful, but modern high-yield additions include: SSRIs and oxcarbazepine. Chlorpropamide is now largely a: Historical association because the drug is rarely used.

Most importantly: SIADH IS A DIAGNOSIS OF EXCLUSION. Low sodium alone does not diagnose SIADH.

Key Clinical Pattern For rapid recall: SIADH = INAPPROPRIATELY HIGH ADH EFFECT → WATER RETENTION → DILUTIONAL HYPONATRAEMIA. Think: SCLC → CLASSIC MALIGNANCY. PNEUMONIA / TB → PULMONARY. MENINGITIS / ENCEPHALITIS / SAH / TRAUMA → CNS. SSRI / CARBAMAZEPINE / OXCARBAZEPINE → DRUGS. The characteristic biochemical pattern is: ↓ SERUM Na⁺  ●  ↓ SERUM OSMOLALITY  ●  INAPPROPRIATELY CONCENTRATED URINE  ●  URINARY Na⁺ NOT SUPPRESSED  ●  CLINICAL EUVOLAEMIA. And remember the opposite patterns: SIADH → TOO MUCH ADH EFFECT → WATER RETAINED → LOW Na⁺. DI → TOO LITTLE ADH EFFECT → WATER LOST → HIGH-VOLUME DILUTE URINE ± HIGH Na⁺.

Medicine – Causes of Diabetes Insipidus

Diabetes insipidus – DI is a disorder of water balance characterised by the production of large volumes of abnormally dilute urine. The resulting excessive urinary water loss produces polyuria and polydipsia, and if the patient cannot replace the lost water, hypernatraemia and dehydration may develop.

The two major forms in the original notes are:

Central DI – reduced secretion of antidiuretic hormone.

Nephrogenic DI – reduced renal response to antidiuretic hormone.

The older term cranial DI is still understood, but central diabetes insipidus is now more commonly used.

1. Normal ADH Physiology

Antidiuretic hormone – ADH, also called:

Arginine vasopressin – AVP,

is synthesised mainly in the:

Supraoptic and paraventricular nuclei of the hypothalamus.

It is transported along axons to the:

Posterior pituitary,

where it is stored and released into the circulation.

2. Action of ADH

ADH acts mainly on:

V₂ receptors

on principal cells of the renal collecting ducts.

This activates signalling that inserts:

Aquaporin-2 water channels

into the luminal membrane.

Therefore:

ADH → V₂ receptor → aquaporin-2 insertion → ↑ water reabsorption → concentrated urine.

3. What Happens in Diabetes Insipidus?

If there is insufficient ADH:

Collecting ducts cannot conserve water effectively.

Alternatively, ADH may be present but the kidneys may fail to respond.

In either situation:

↓ Water reabsorption

↓

Large-volume dilute urine

↓

Polyuria

↓

Thirst and polydipsia

↓

If water intake is inadequate:

Hypernatraemia + increased plasma osmolality + dehydration.

4. Central Diabetes Insipidus

Central DI results from inadequate synthesis or secretion of:

ADH/AVP.

Therefore:

↓ ADH secretion → collecting duct cannot maximally concentrate urine → excessive free-water loss.

The major causes include:

Idiopathic/autoimmune disease.

Pituitary or hypothalamic surgery.

Trauma.

Tumours.

Infiltrative diseases.

Genetic disorders.

5. Idiopathic Central DI

The original notes correctly include:

Idiopathic central DI.

This means no obvious structural cause is identified during the initial evaluation.

Some cases previously classified as idiopathic are now recognised to have:

Autoimmune

or other identifiable mechanisms.

Therefore appropriate follow-up may still be required.

6. Pituitary Surgery

The original notes correctly identify:

Pituitary surgery

as an important cause.

Surgery around the:

Hypothalamus.

Pituitary stalk.

Posterior pituitary.

can disrupt the hypothalamic neurons or axons responsible for ADH transport and release.

Therefore:

PITUITARY/HYPOTHALAMIC SURGERY → ↓ ADH → CENTRAL DI.

7. Postoperative DI

Central DI may appear after surgery involving the pituitary region.

Depending on the degree of injury, it may be:

Transient

or

Permanent.

Patients require careful monitoring of:

Urine output.

Serum sodium.

Fluid balance.

8. Infiltrative Hypothalamic Disease

Infiltrative diseases can damage the:

Hypothalamus

or

Pituitary stalk.

The original notes correctly include:

Sarcoidosis

and

Histiocytosis X.

9. Sarcoidosis

Sarcoidosis can involve the hypothalamic–pituitary region as part of:

Neurosarcoidosis.

Granulomatous infiltration can interfere with ADH production or release.

Therefore:

SARCOIDOSIS → HYPOTHALAMIC/PITUITARY INFILTRATION → CENTRAL DI.

Interestingly, sarcoidosis can also contribute to nephrogenic DI indirectly through hypercalcaemia, which impairs the kidney’s concentrating ability.

10. Histiocytosis X

The older term:

Histiocytosis X

is now generally replaced by:

Langerhans cell histiocytosis – LCH.

LCH can infiltrate the:

Hypothalamic–pituitary axis.

Central DI is an important endocrine manifestation.

Therefore:

LCH + POLYURIA/POLYDIPSIA → CONSIDER CENTRAL DI.

11. Craniopharyngioma

The original notes correctly include:

Craniopharyngioma.

These tumours occur close to the:

Pituitary stalk and hypothalamus.

They may damage the ADH-producing or transporting system.

Therefore central DI may develop either from the:

Tumour itself

or following:

Surgery for the tumour.

12. Other Tumours

Other masses affecting the hypothalamic–pituitary region may also cause central DI.

Examples include selected:

Germ-cell tumours.

Metastases.

Other suprasellar lesions.

The important principle is:

Damage to the hypothalamus or pituitary stalk can impair ADH secretion.

13. Trauma

The original notes correctly include:

Trauma.

Severe head injury may damage the:

Hypothalamus.

Pituitary stalk.

Posterior pituitary pathway.

This can produce:

Transient or permanent central DI.

14. Familial Central DI

Rare genetic disorders can cause central DI.

These may involve abnormalities in:

AVP synthesis or processing.

Some familial forms are inherited in an:

Autosomal dominant pattern.

15. DIDMOAD Syndrome

The original notes correctly identify:

DIDMOAD syndrome.

DIDMOAD stands for:

Diabetes Insipidus.

Diabetes Mellitus.

Optic Atrophy.

Deafness.

This disorder is also known as:

Wolfram syndrome.

16. Wolfram Syndrome

Wolfram syndrome is a rare genetic neurodegenerative disorder, classically associated with:

Juvenile-onset diabetes mellitus.

Optic atrophy.

Central diabetes insipidus.

Sensorineural deafness.

Therefore:

DIDMOAD = DI + DM + OPTIC ATROPHY + DEAFNESS.

This is a useful examination mnemonic.

17. Nephrogenic Diabetes Insipidus

In nephrogenic DI, ADH is produced and released, but the kidneys are:

Resistant to its action.

Therefore:

ADH present

↓

Kidney fails to respond adequately

↓

Aquaporin-mediated water reabsorption impaired

↓

Large-volume dilute urine.

18. Causes of Nephrogenic DI

Nephrogenic DI can be:

Inherited

or

Acquired.

Acquired causes are considerably more common and include:

Lithium.

Hypercalcaemia.

Hypokalaemia.

Kidney disease.

Post-obstructive states.

Other medications can also impair renal concentrating ability.

19. Inherited Nephrogenic DI

The original notes state:

Primary X-linked or dominant.

This requires some refinement.

The most common inherited form is:

X-linked nephrogenic DI

caused by abnormalities in the:

AVPR2 gene, which encodes the renal V₂ vasopressin receptor.

20. Aquaporin-2 Mutations

Other inherited forms are caused by mutations involving:

Aquaporin-2 – AQP2.

These can be:

Autosomal recessive

or, less commonly:

Autosomal dominant.

Therefore the inheritance pattern depends on the molecular defect.

21. Hypercalcaemia

The original notes correctly identify:

Hypercalcaemia

as a cause of nephrogenic DI.

Persistent high calcium interferes with the kidney’s ability to:

Concentrate urine.

It impairs responsiveness of the collecting duct to ADH and can affect the medullary concentration gradient.

Therefore:

HYPERCALCAEMIA → IMPAIRED URINARY CONCENTRATION → POLYURIA → NEPHROGENIC DI.

22. Hypokalaemia

The original notes also correctly include:

Hypokalaemia.

Persistent potassium deficiency reduces the kidney’s ability to concentrate urine and can impair:

Aquaporin-2 expression and collecting-duct responsiveness.

Therefore:

HYPOKALAEMIA → ADH RESISTANCE/IMPAIRED CONCENTRATION → NEPHROGENIC DI.

23. Chronic Kidney Disease and Tubulointerstitial Disease

Several forms of renal disease impair the kidney’s concentrating ability.

The original notes include:

Chronic pyelonephritis.

Adult polycystic kidney disease.

Post-urinary obstruction.

These can produce a nephrogenic DI-like concentrating defect.

24. Chronic Pyelonephritis

Chronic tubulointerstitial injury can damage the structures required to maintain:

The renal medullary concentration gradient.

As a result, the kidney becomes less capable of concentrating urine even when ADH is present.

Therefore:

CHRONIC TUBULOINTERSTITIAL DAMAGE → IMPAIRED CONCENTRATING ABILITY → POLYURIA.

25. ADPKD

The older term:

Adult polycystic kidney disease

is better expressed as:

Autosomal dominant polycystic kidney disease – ADPKD.

Structural disruption of the renal medulla can impair urinary concentrating ability.

Patients may therefore develop:

Polyuria and nocturia, particularly as renal disease progresses.

26. Post-Urinary Obstruction

The original notes correctly include:

Post-urinary obstruction.

After relief of significant urinary obstruction, patients may develop:

Post-obstructive diuresis.

Tubular dysfunction and reduced responsiveness to ADH may contribute to very large urine volumes.

This can cause substantial losses of:

Water and electrolytes.

27. Lithium

The original notes correctly identify:

Lithium

as a major drug cause of nephrogenic DI.

This is one of the most important acquired causes.

Lithium enters collecting-duct principal cells and interferes with:

ADH signalling

and

Aquaporin-2 expression/function.

Therefore:

LITHIUM → COLLECTING-DUCT ADH RESISTANCE → NEPHROGENIC DI.

28. Clinical Importance of Lithium

Patients taking chronic lithium therapy may develop:

Polyuria.

Polydipsia.

Impaired urinary concentrating ability.

The concentrating defect can sometimes persist even after lithium is discontinued, particularly after prolonged exposure.

29. Demeclocycline

The original notes correctly include:

Demeclocycline.

Demeclocycline reduces renal responsiveness to:

ADH.

It can therefore intentionally produce a form of:

Nephrogenic DI.

Historically, this effect has been used in selected patients with:

SIADH.

Its use is now more limited because of concerns such as:

Nephrotoxicity and the availability of other approaches.

30. Glibenclamide – Important Correction

The original notes include:

Glibenclamide

as a cause of nephrogenic DI.

This is not a standard modern cause of nephrogenic diabetes insipidus and should not be memorised as one of the major drug associations.

The high-yield drug causes are much more importantly:

Lithium.

Demeclocycline.

Other recognised drug-related causes include selected nephrotoxic agents that impair tubular function.

31. Sarcoidosis and Nephrogenic DI

The original notes also list:

Sarcoidosis

under nephrogenic DI.

This can occur indirectly because sarcoidosis may produce:

Hypercalcaemia.

Hypercalcaemia then impairs the renal response to ADH.

Therefore sarcoidosis can potentially contribute to DI by two different mechanisms:

Hypothalamic/pituitary involvement → central DI.

or

Hypercalcaemia → nephrogenic DI.

32. Clinical Features of DI

The characteristic symptoms are:

Polyuria.

Polydipsia.

Nocturia.

The urine is:

Dilute.

Patients often develop a strong preference for:

Cold water.

33. Hypernatraemia

If thirst is intact and water is freely available, patients can often compensate for urinary losses by drinking large quantities of water.

Therefore serum sodium may remain:

Normal.

However, if the patient cannot obtain enough water:

Free-water loss exceeds intake

↓

Serum Na⁺ rises

↓

Plasma osmolality rises

↓

Hypernatraemic dehydration develops.

34. When DI Becomes Particularly Dangerous

DI becomes especially dangerous in patients who:

Cannot communicate thirst.

Cannot access water.

Are unconscious.

Are very young.

Have neurological impairment.

These patients can develop severe:

Hypernatraemia and dehydration.

35. Diagnosis

The first step is to establish that the patient truly has:

Hypotonic polyuria.

This requires distinguishing DI from other causes of frequent or excessive urination.

Important measurements include:

24-hour urine volume.

Urine osmolality.

Serum sodium.

Plasma osmolality.

Glucose.

Calcium.

Potassium.

Renal function.

36. Exclude Osmotic Diuresis

A major differential diagnosis is:

Diabetes mellitus.

In uncontrolled diabetes mellitus:

Glucose spills into urine

↓

Water follows glucose

↓

Osmotic diuresis

↓

Polyuria.

The urine in diabetes mellitus may therefore have a relatively high osmolality because of:

Glucose.

In DI, the urine is characteristically:

Inappropriately dilute.

37. Primary Polydipsia

Another important differential is:

Primary polydipsia.

Here the primary problem is:

Excessive water intake

rather than failure of ADH production or action.

Excess water intake suppresses ADH and produces:

Dilute urine.

Therefore distinguishing primary polydipsia from partial DI can sometimes be challenging.

38. Water-Deprivation Testing

Traditionally, selected patients were investigated using a supervised:

Water-deprivation test.

The principle is to determine whether the kidney can appropriately concentrate urine when water is withheld.

In healthy physiology:

Water deprivation → ↑ ADH → concentrated urine.

In DI:

Urine remains inappropriately dilute.

Because dehydration can become dangerous, this test requires:

Careful specialist supervision.

39. Desmopressin Response

Desmopressin – DDAVP is an ADH analogue.

After desmopressin:

Central DI → urine concentration rises substantially, because the missing hormone has been replaced.

In:

Nephrogenic DI → little or no appropriate response, because the kidney remains resistant to ADH.

Partial forms may show intermediate responses.

40. Copeptin – Modern Diagnostic Addition

Modern specialist evaluation may use:

Copeptin.

Copeptin is released with endogenous vasopressin and is easier to measure reliably than ADH itself.

Stimulated copeptin-based testing can help distinguish:

Central DI.

Nephrogenic DI.

Primary polydipsia.

This is increasingly important in specialist diagnostic pathways.

41. Treatment of Central DI

The major treatment for established central DI is:

Desmopressin – DDAVP.

It acts mainly at renal:

V₂ receptors

and increases collecting-duct water reabsorption.

Therefore:

DESMOPRESSIN → ↑ WATER REABSORPTION → ↓ URINE VOLUME.

42. Desmopressin Safety

Excessive desmopressin combined with excessive water intake can cause:

Water retention

and

Hyponatraemia.

Therefore therapy requires appropriate monitoring and patient education.

The underlying cause of central DI should also be treated when possible.

43. Treatment of Nephrogenic DI

Treatment begins by correcting the cause.

Examples include:

Correct hypercalcaemia.

Correct hypokalaemia.

Review or stop lithium when clinically appropriate.

Treat underlying renal disease.

Adequate access to water is essential.

44. Thiazides in Nephrogenic DI

Paradoxically:

Thiazide diuretics

can reduce urine volume in nephrogenic DI.

They cause mild volume contraction, increasing proximal sodium and water reabsorption.

Therefore less fluid reaches the distal nephron.

The result is:

Reduced urine volume.

45. Amiloride and Lithium-Induced DI

In lithium-induced nephrogenic DI:

Amiloride

can be particularly useful because it blocks:

ENaC

and reduces lithium entry into collecting-duct principal cells.

Therefore:

LITHIUM-INDUCED DI → CONSIDER AMILORIDE.

46. Central DI – Note Form

CENTRAL DI = TOO LITTLE ADH.

Idiopathic/autoimmune.

Pituitary/hypothalamic surgery.

Trauma.

Infiltrative disease:

Sarcoidosis.

Langerhans cell histiocytosis.

Tumours:

Craniopharyngioma.

Other hypothalamic/pituitary stalk lesions.

Genetic:

Familial central DI.

Wolfram syndrome – DIDMOAD.

47. Nephrogenic DI – Note Form

NEPHROGENIC DI = ADH PRESENT BUT KIDNEY DOES NOT RESPOND PROPERLY.

Inherited:

X-linked AVPR2 mutations.

AQP2 mutations – usually AR, sometimes AD.

Electrolytes:

Hypercalcaemia.

Hypokalaemia.

Renal disease:

Chronic tubulointerstitial disease/chronic pyelonephritis.

ADPKD with concentrating defect.

Post-obstructive state.

Drugs:

Lithium – particularly important.

Demeclocycline.

Other causes of significant tubular injury.

Sarcoidosis:

Can cause nephrogenic concentrating impairment indirectly through:

Hypercalcaemia.

48. Central Versus Nephrogenic DI – Copyable Comparison

CENTRAL DI

Problem:

↓ ADH secretion.

Site of defect:

Hypothalamus/posterior pituitary pathway.

Desmopressin:

Urine concentrating response present, especially in complete central DI.

Typical causes:

Surgery, trauma, craniopharyngioma, sarcoidosis, LCH, idiopathic/autoimmune and genetic disease.

NEPHROGENIC DI

Problem:

↓ renal response to ADH.

Site of defect:

Kidney/collecting duct.

Desmopressin:

Little or no response in complete nephrogenic DI.

Typical causes:

Lithium, hypercalcaemia, hypokalaemia, renal tubular disease and inherited AVPR2/AQP2 abnormalities.

49. Important Clarifications to the Original Notes

The term:

“Cranial DI”

is valid historically, but:

Central diabetes insipidus

is the more commonly used modern term.

ADH is:

Synthesised in the hypothalamus

and then:

Transported to and released from the posterior pituitary.

Therefore central DI may result from damage anywhere along this pathway.

The older term:

Histiocytosis X

should generally be replaced by:

Langerhans cell histiocytosis.

The original inherited nephrogenic DI description of:

“X-linked or dominant”

needs refinement:

AVPR2 mutations → usually X-linked.

AQP2 mutations → usually autosomal recessive, occasionally autosomal dominant.

The original inclusion of:

Glibenclamide

as a major drug cause is outdated and should not be prioritised.

The major examination drug association is:

LITHIUM → NEPHROGENIC DI.

Key Clinical Pattern

For rapid recall:

DI → POLYURIA + POLYDIPSIA + LARGE VOLUMES OF DILUTE URINE.

CENTRAL DI = NOT ENOUGH ADH.

Think:

PITUITARY SURGERY.

HEAD TRAUMA.

CRANIOPHARYNGIOMA.

SARCOIDOSIS.

LANGERHANS CELL HISTIOCYTOSIS.

WOLFRAM/DIDMOAD.

NEPHROGENIC DI = KIDNEYS DO NOT RESPOND TO ADH.

Think:

LITHIUM.

HYPERCALCAEMIA.

HYPOKALAEMIA.

RENAL TUBULAR/CHRONIC KIDNEY DISEASE.

AVPR2/AQP2 MUTATIONS.

And remember the classic treatment distinction:

CENTRAL DI → DESMOPRESSIN.

NEPHROGENIC DI → CORRECT CAUSE ± THIAZIDE; AMILORIDE PARTICULARLY USEFUL FOR LITHIUM-INDUCED DI.

Medicine – Causes of Hypokalaemia

Hypokalaemia is a reduction in serum potassium concentration, usually defined as:

K⁺ <3.5 mmol/L.

Potassium is the major intracellular cation and is essential for normal neuromuscular function, skeletal-muscle contraction and cardiac electrical activity. Significant hypokalaemia can therefore cause weakness, paralysis and potentially dangerous cardiac arrhythmias.

The causes can be understood through three major mechanisms:

Decreased potassium intake.

Increased potassium loss from the body.

Redistribution of potassium from extracellular fluid into cells.

1. Decreased Potassium Intake

Reduced dietary potassium intake alone is an:

Uncommon cause of hypokalaemia.

This is because potassium is widely distributed in food and the kidneys can reduce urinary potassium excretion when intake falls.

Therefore substantial hypokalaemia from reduced intake usually requires:

Severe or prolonged nutritional deficiency

or another contributing mechanism.

2. Starvation

The original notes correctly identify:

Starvation

as a situation in which oral potassium intake can become sufficiently low to contribute to hypokalaemia.

Patients with prolonged:

Malnutrition.

Anorexia.

Starvation.

may develop depletion of total-body potassium.

Other electrolyte deficiencies, particularly:

Magnesium and phosphate deficiency,

may coexist.

3. Inadequate Parenteral Potassium

Hospitalised patients who cannot eat and receive prolonged intravenous fluids without sufficient potassium replacement may develop:

Hypokalaemia.

This is especially likely when there are simultaneous ongoing potassium losses from:

Urine.

Vomiting.

Diarrhoea.

Nasogastric drainage.

Therefore the original note:

“Parenteral”

refers more accurately to inadequate potassium provision during parenteral therapy.

4. Increased Potassium Loss

Increased potassium loss is one of the most important mechanisms of hypokalaemia.

Losses can occur through:

Gastrointestinal tract

or

Kidneys.

A useful clinical question is therefore:

Is the potassium being lost through the gut or through the urine?

5. Gastrointestinal Potassium Loss

Important gastrointestinal causes include:

Vomiting.

Severe diarrhoea.

Laxative/purgative abuse.

Villous adenoma.

Other causes include prolonged gastrointestinal drainage and some fistulas.

6. Vomiting

The original notes correctly include:

Vomiting.

However, an important physiological point is that hypokalaemia from vomiting is not simply due to large amounts of potassium being lost directly in vomit.

Gastric fluid contains mainly:

Hydrogen ions and chloride.

The major potassium loss occurs secondarily through the:

Kidneys.

7. Why Vomiting Causes Hypokalaemia

Persistent vomiting causes:

Loss of HCl

↓

Metabolic alkalosis

• ●

Volume and chloride depletion

↓

Activation of:

Renin–angiotensin–aldosterone system – RAAS

↓

↑ Aldosterone

↓

↑ Distal sodium reabsorption

↓

↑ Renal K⁺ secretion

↓

Hypokalaemia.

Therefore:

VOMITING → METABOLIC ALKALOSIS + SECONDARY HYPERALDOSTERONISM → RENAL K⁺ LOSS.

8. Severe Diarrhoea

The original notes correctly identify:

Severe diarrhoea

as an important cause.

Intestinal fluid contains significant potassium.

Therefore prolonged high-volume diarrhoea can cause direct:

Gastrointestinal K⁺ loss.

9. Diarrhoea and Acid–Base Balance

Diarrhoea also causes loss of:

Bicarbonate.

Therefore the classic biochemical pattern is:

Hypokalaemia

• ●

Normal-anion-gap metabolic acidosis.

This contrasts with vomiting, which typically produces:

Hypokalaemia + metabolic alkalosis.

10. Purgative or Laxative Abuse

Chronic excessive use of laxatives can produce:

Persistent diarrhoea

and therefore:

Potassium depletion.

Severe laxative abuse may result in substantial electrolyte disturbances and volume depletion.

Therefore:

LAXATIVE ABUSE → DIARRHOEA → GI K⁺ LOSS → HYPOKALAEMIA.

11. Villous Adenoma

A large secretory:

Villous adenoma of the colon or rectum

can produce substantial amounts of watery, electrolyte-rich diarrhoea.

This can cause:

Hypokalaemia.

Volume depletion.

Renal impairment.

The severe secretory syndrome associated with a large villous adenoma is sometimes called:

McKittrick–Wheelock syndrome.

12. Renal Potassium Loss

The kidneys are another major route of excessive potassium loss.

Important renal causes include:

Thiazide diuretics.

Loop diuretics.

Renal tubular disorders.

Mineralocorticoid excess.

Hypomagnesaemia.

13. Thiazide Diuretics

The original notes correctly include:

Thiazides.

Examples include:

Bendroflumethiazide.

Hydrochlorothiazide.

Indapamide.

Thiazides inhibit sodium chloride reabsorption in the:

Distal convoluted tubule.

This increases sodium delivery to the collecting duct.

14. Why Thiazides Cause Hypokalaemia

More sodium reaches the distal nephron.

↓

More sodium enters principal cells through:

ENaC.

↓

The lumen becomes relatively negative.

↓

Potassium secretion increases.

↓

Hypokalaemia.

Volume contraction also activates:

RAAS and aldosterone,

further promoting potassium loss.

15. Loop Diuretics

Loop diuretics such as:

Furosemide

inhibit the:

Na⁺-K⁺-2Cl⁻ cotransporter – NKCC2

in the thick ascending limb of the loop of Henle.

This increases distal sodium delivery and promotes:

Renal potassium excretion.

Therefore:

LOOP DIURETICS → HYPOKALAEMIA.

16. Diuretics and Metabolic Alkalosis

Both loop and thiazide diuretics commonly produce:

Hypokalaemia

and

Metabolic alkalosis.

This occurs through increased distal sodium delivery, volume contraction and increased aldosterone activity.

Therefore:

DIURETIC + LOW K⁺ + METABOLIC ALKALOSIS

is a classic clinical pattern.

17. Renal Tubular Damage

The original notes include:

Renal tubular damage.

Tubular disorders can impair normal electrolyte handling and cause inappropriate urinary potassium loss.

Examples include certain:

Tubulointerstitial diseases.

Drug-induced tubular injury.

Inherited tubular disorders.

The exact acid–base pattern depends on which part of the nephron is affected.

18. Renal Tubular Acidosis

Certain forms of:

Renal tubular acidosis – RTA

are associated with hypokalaemia.

These include:

Type 1 – distal RTA.

Type 2 – proximal RTA.

Both can produce:

Hypokalaemic normal-anion-gap metabolic acidosis.

In contrast:

Type 4 RTA causes hyperkalaemia.

19. Hypomagnesaemia

An important additional cause of persistent renal potassium loss is:

Hypomagnesaemia.

Low magnesium increases renal potassium secretion.

Therefore:

↓ Mg²⁺ → ↑ renal K⁺ wasting → hypokalaemia.

This is particularly important when potassium remains low despite replacement.

20. Refractory Hypokalaemia

A high-yield clinical rule is:

HYPOKALAEMIA THAT DOES NOT CORRECT → CHECK MAGNESIUM.

Potassium replacement may be ineffective until associated magnesium deficiency is also corrected.

21. Endocrine Causes

The original notes identify three important mineralocorticoid-related causes:

Primary hyperaldosteronism.

Cushing syndrome.

Excess liquorice consumption.

These conditions increase renal potassium excretion.

22. Primary Hyperaldosteronism – Conn Syndrome

In primary hyperaldosteronism:

Aldosterone production is excessive and relatively autonomous.

Aldosterone increases sodium reabsorption through ENaC in the collecting duct while increasing:

Potassium secretion

and

Hydrogen ion secretion.

Therefore the classic pattern is:

Hypertension + hypokalaemia + metabolic alkalosis.

23. Renin and Aldosterone in Primary Hyperaldosteronism

Because sodium retention expands extracellular volume, renin secretion becomes suppressed.

Therefore:

Aldosterone ↑

while:

Renin ↓.

This produces an increased:

Aldosterone-to-renin ratio.

However, not every patient with primary aldosteronism is hypokalaemic; many are:

Normokalaemic.

24. Cushing Syndrome

In severe cortisol excess, cortisol can exert:

Mineralocorticoid effects.

This increases sodium retention and promotes renal:

Potassium and hydrogen ion loss.

Therefore severe Cushing syndrome may produce:

Hypertension.

Hypokalaemia.

Metabolic alkalosis.

25. Liquorice

The original notes correctly identify:

Excess liquorice

as a cause of hypokalaemia.

However, liquorice does not simply contain a conventional mineralocorticoid.

Its active component:

Glycyrrhetinic acid

inhibits:

11β-hydroxysteroid dehydrogenase type 2 – 11β-HSD2.

26. Mechanism of Liquorice-Induced Hypokalaemia

Normally 11β-HSD2 converts:

Cortisol → cortisone

within mineralocorticoid-sensitive tissues.

When the enzyme is inhibited:

Cortisol activates mineralocorticoid receptors.

↓

↑ Na⁺ retention

↓

↑ K⁺ and H⁺ excretion

↓

Hypertension + hypokalaemia + metabolic alkalosis.

This resembles mineralocorticoid excess.

27. Redistribution Into Cells

Hypokalaemia does not always mean potassium has been lost from the body.

Sometimes total-body potassium is relatively preserved, but potassium moves:

From extracellular fluid → into cells.

This lowers the measured serum potassium.

Important causes include:

Metabolic alkalosis.

Insulin.

β₂-adrenergic agonists.

Correction of severe megaloblastic anaemia.

Hypothermia.

28. Metabolic Alkalosis

The original notes correctly include:

Metabolic alkalosis.

During alkalosis, potassium tends to shift:

Into cells.

Hydrogen ions move in the opposite direction to help maintain electroneutrality.

Additionally, many causes of metabolic alkalosis, such as vomiting and diuretic therapy, simultaneously cause:

Renal potassium loss.

Therefore hypokalaemia and metabolic alkalosis commonly reinforce one another.

29. Insulin

The original notes correctly identify:

Insulin.

Insulin stimulates:

Na⁺/K⁺-ATPase.

This drives potassium:

From extracellular fluid → into cells.

Therefore insulin lowers serum potassium.

30. Clinical Importance of Insulin

This physiological effect is deliberately used when treating:

Hyperkalaemia.

Intravenous insulin with glucose shifts potassium into cells and temporarily lowers serum K⁺.

Conversely, excessive insulin activity can contribute to:

Hypokalaemia.

31. β-Adrenergic Agonists

The original notes correctly include:

β-adrenergic agonists, particularly β₂ agonists such as:

Salbutamol.

β₂-receptor stimulation increases Na⁺/K⁺-ATPase activity.

Therefore:

Salbutamol → K⁺ moves into cells → serum K⁺ falls.

This is also why nebulised salbutamol can be used as an adjunct in the treatment of:

Hyperkalaemia.

32. Vitamin B12 or Folate Treatment

The original notes include:

Vitamin B12 or folic acid when correcting megaloblastic anaemia.

This is a recognised but less common mechanism.

When severe megaloblastic anaemia is treated, effective erythropoiesis can increase rapidly.

New cells take up:

Potassium.

Therefore serum potassium can transiently fall.

33. Mechanism During Haematological Recovery

Vitamin B12/folate treatment

↓

Rapid increase in erythropoiesis

↓

Increased cellular uptake of K⁺

↓

Transient hypokalaemia.

This is most relevant in patients with severe deficiency undergoing brisk marrow recovery.

34. Hypothermia

The original notes also include:

Hypothermia.

Hypothermia can cause potassium to move:

Into cells

and may increase renal potassium loss.

Therefore serum potassium may fall during significant hypothermia.

An important clinical consideration is that potassium may rise again during:

Rewarming.

35. Clinical Features of Hypokalaemia

Mild hypokalaemia may be:

Asymptomatic.

With increasing severity, patients may develop:

Fatigue.

Muscle weakness.

Muscle cramps.

Constipation or ileus.

Paraesthesiae.

Severe deficiency can cause:

Flaccid paralysis.

Respiratory muscle weakness.

Cardiac arrhythmias.

36. ECG Changes

Hypokalaemia can produce characteristic ECG abnormalities.

These may include:

Flattened or inverted T waves.

ST-segment depression.

Prominent U waves.

Apparent QT/QU prolongation.

Severe hypokalaemia increases susceptibility to:

Atrial and ventricular arrhythmias.

37. Hypokalaemia and Digoxin

Hypokalaemia increases myocardial sensitivity to:

Digoxin.

Therefore a patient receiving digoxin who develops significant hypokalaemia has an increased risk of:

Digoxin toxicity and arrhythmias.

This is particularly important when hypokalaemia is caused by:

Loop or thiazide diuretics.

38. Investigation

The first step is to confirm the potassium abnormality and look for the underlying mechanism.

Useful investigations include:

Serum electrolytes.

Magnesium.

Renal function.

Bicarbonate/acid–base status.

ECG when clinically significant.

If the cause remains uncertain, urinary potassium can help determine whether potassium loss is:

Renal or extrarenal.

39. Urinary Potassium

Conceptually:

Low urinary K⁺ during hypokalaemia

suggests that the kidneys are appropriately conserving potassium.

This points toward:

GI loss, poor intake or intracellular redistribution.

In contrast:

Inappropriately high urinary K⁺

suggests:

Renal potassium wasting.

This may occur with:

Diuretics.

Mineralocorticoid excess.

Renal tubular disorders.

Hypomagnesaemia.

40. Blood Pressure and Acid–Base Status

A particularly useful diagnostic approach is to combine:

Blood pressure

with

Acid–base status.

For example:

Hypokalaemia + metabolic alkalosis + hypertension

suggests:

Mineralocorticoid excess, such as primary aldosteronism.

Hypokalaemia + metabolic alkalosis + normal/low BP

suggests possibilities such as:

Vomiting.

Diuretics.

Bartter syndrome.

Gitelman syndrome.

Hypokalaemia + metabolic acidosis

suggests:

Diarrhoea

or

Type 1/type 2 RTA, among other causes.

41. Treatment Principles

Treatment depends on:

Severity of hypokalaemia.

Symptoms.

ECG abnormalities.

Underlying cause.

Renal function.

Presence of hypomagnesaemia.

The underlying potassium loss or redistribution should be corrected whenever possible.

42. Potassium Replacement

Mild-to-moderate hypokalaemia is often treated with:

Oral potassium replacement.

More severe or symptomatic hypokalaemia may require carefully controlled:

Intravenous potassium replacement

with appropriate monitoring.

Intravenous potassium must be administered cautiously because excessive or rapid administration can cause:

Dangerous hyperkalaemia and cardiac arrhythmias.

43. Correct Magnesium

If hypomagnesaemia is present:

Replace magnesium as well.

Otherwise continued renal potassium wasting can make hypokalaemia:

Difficult or impossible to correct adequately.

44. Causes of Hypokalaemia – Note Form

DECREASED INTAKE:

Starvation/severe malnutrition.

Inadequate potassium during prolonged parenteral therapy.

Usually insufficient alone unless prolonged or combined with other losses.

GI LOSS:

Vomiting.

Severe diarrhoea.

Purgative/laxative abuse.

Villous adenoma.

RENAL LOSS:

Thiazide diuretics.

Loop diuretics.

Renal tubular disease.

Type 1 and type 2 RTA.

Hypomagnesaemia.

ENDOCRINE/MINERALOCORTICOID:

Primary hyperaldosteronism – Conn syndrome.

Cushing syndrome.

Excess liquorice.

REDISTRIBUTION INTO CELLS:

Metabolic alkalosis.

Insulin.

β₂ agonists such as salbutamol.

B12/folate treatment during brisk recovery from severe megaloblastic anaemia.

Hypothermia.

45. Acid–Base Patterns – Note Form

Vomiting:

Hypokalaemia

• ●

Metabolic alkalosis.

Loop/thiazide diuretics:

Hypokalaemia

• ●

Metabolic alkalosis.

Primary hyperaldosteronism:

Hypertension

• ●

Hypokalaemia

• ●

Metabolic alkalosis.

Severe diarrhoea:

Hypokalaemia

• ●

Normal-anion-gap metabolic acidosis.

Type 1 or type 2 RTA:

Hypokalaemia

• ●

Normal-anion-gap metabolic acidosis.

46. Important Clarifications to the Original Notes

The original list is broadly correct.

Reduced oral intake alone is an uncommon cause unless severe or prolonged, such as starvation.

Vomiting causes hypokalaemia mainly through:

Volume/chloride depletion → RAAS activation → aldosterone-mediated renal K⁺ loss, rather than simply direct potassium loss from gastric fluid.

Excess liquorice does not literally act simply as an ingested mineralocorticoid. It inhibits:

11β-HSD2

allowing cortisol to activate mineralocorticoid receptors.

An important addition to the original list is:

Hypomagnesaemia, because it causes renal potassium wasting and is a major reason hypokalaemia may fail to respond to potassium replacement.

Key Clinical Pattern

For rapid recall:

HYPOKALAEMIA = LOW INTAKE, LOSS, OR SHIFT INTO CELLS.

Think:

VOMITING → LOW K⁺ + METABOLIC ALKALOSIS.

DIARRHOEA → LOW K⁺ + NORMAL-GAP METABOLIC ACIDOSIS.

LOOP/THIAZIDE → LOW K⁺ + METABOLIC ALKALOSIS.

CONN → HYPERTENSION + LOW K⁺ + METABOLIC ALKALOSIS.

INSULIN / SALBUTAMOL → K⁺ SHIFTS INTO CELLS.

LOW Mg²⁺ → RENAL K⁺ WASTING → REFRACTORY HYPOKALAEMIA.

For the ECG:

FLAT T WAVES + ST DEPRESSION + PROMINENT U WAVES → THINK HYPOKALAEMIA.

And the particularly useful clinical rule is:

HYPOKALAEMIA THAT WILL NOT CORRECT → CHECK AND REPLACE MAGNESIUM.

Medicine – Hyperkalaemia

Hyperkalaemia is an abnormally high serum potassium concentration. It is clinically important because potassium strongly influences the resting membrane potential of cardiac and skeletal muscle cells, and severe hyperkalaemia can cause rapidly progressive conduction abnormalities, ventricular arrhythmias and cardiac arrest.

A commonly used definition is:

Serum K⁺ >5.0–5.5 mmol/L, depending on the laboratory.

The urgency of treatment depends not only on the potassium concentration but also on the ECG, symptoms, rate of rise, renal function and underlying cause.

1. Major Mechanisms of Hyperkalaemia

The causes can be divided into four useful groups:

Spurious or pseudohyperkalaemia.

Excess potassium administration.

Reduced renal potassium excretion.

Redistribution of potassium from cells into extracellular fluid.

This classification helps determine whether the patient has genuine excess total-body potassium or simply a shift of potassium from the intracellular to extracellular compartment.

2. Spurious Hyperkalaemia

Before treating an unexpected potassium result, consider:

Pseudohyperkalaemia.

This means the measured potassium is elevated in the blood sample even though the patient’s true circulating potassium is not significantly elevated.

The classic cause is:

Haemolysis of the blood sample.

3. Haemolysis

Red blood cells contain a high intracellular concentration of potassium.

If red cells rupture during or after venepuncture:

Intracellular K⁺ is released into the sample.

↓

Laboratory potassium rises.

↓

Falsely elevated potassium result.

Therefore:

UNEXPECTED HIGH K⁺ + HAEMOLYSED SAMPLE → CONSIDER PSEUDOHYPERKALAEMIA.

However, if the potassium is severely elevated or the ECG is abnormal, urgent management should not be delayed simply while waiting for a repeat result.

4. Other Causes of Pseudohyperkalaemia

Pseudohyperkalaemia can also occur with:

Difficult or traumatic venepuncture.

Prolonged tourniquet application.

Repeated fist clenching during blood collection.

Marked thrombocytosis.

Marked leukocytosis.

Therefore the blood result should always be interpreted in its clinical context.

5. Excessive Potassium Intake

The original notes place excessive intake under “spurious,” but this requires correction.

Excessive potassium intake causes genuine hyperkalaemia, not pseudohyperkalaemia.

This may occur from:

Excessive intravenous potassium administration.

Excessive oral potassium supplements.

Potassium-containing salt substitutes.

Dietary potassium alone rarely causes severe hyperkalaemia when renal function and aldosterone activity are normal because healthy kidneys can increase potassium excretion.

The risk becomes much greater in:

Kidney failure or impaired aldosterone activity.

6. Decreased Renal Potassium Excretion

The kidneys are the major route for potassium elimination.

Therefore:

Reduced renal K⁺ excretion

is one of the most important mechanisms of hyperkalaemia.

Major causes include:

Acute kidney injury.

Chronic kidney disease.

Hypoaldosteronism.

Addison disease.

Potassium-retaining medications.

7. Acute Kidney Injury

The older term:

Acute oliguric renal failure

is now generally replaced by:

Acute kidney injury – AKI.

Severe AKI, particularly when associated with:

Oliguria or anuria,

can markedly reduce urinary potassium excretion.

Therefore potassium accumulates in the extracellular fluid.

8. Why Hyperkalaemia Is Dangerous in AKI

AKI may simultaneously produce:

Reduced potassium excretion

and

Metabolic acidosis.

Acidosis may further increase extracellular potassium in some settings.

Therefore:

AKI + OLIGURIA + ACIDOSIS → HIGH RISK OF HYPERKALAEMIA.

Severe refractory hyperkalaemia is an important indication for:

Urgent dialysis.

9. Chronic Kidney Disease

The older term:

Chronic renal failure

is now generally replaced by:

Chronic kidney disease – CKD.

As functioning nephron mass falls, the kidneys become progressively less able to excrete potassium.

Adaptive mechanisms can maintain potassium balance for a considerable period, so severe hyperkalaemia is particularly likely in:

Advanced CKD

or when an additional precipitant is present.

10. Common Precipitants in CKD

A patient with CKD may develop hyperkalaemia after:

AKI.

Dehydration.

ACE inhibitor or ARB therapy.

Potassium-sparing diuretics.

NSAIDs.

Excess potassium supplementation.

Metabolic acidosis.

Therefore medication review is essential.

11. Aldosterone and Potassium

Aldosterone normally acts on the distal nephron to promote:

Sodium reabsorption

and

Potassium secretion.

Therefore:

↓ Aldosterone production or action → ↓ renal K⁺ excretion → hyperkalaemia.

12. Addison Disease

Addison disease, or primary adrenal insufficiency, causes deficiency of:

Aldosterone

and

Cortisol.

Aldosterone deficiency reduces renal potassium excretion.

Therefore:

ADDISON DISEASE → ↓ ALDOSTERONE → K⁺ RETENTION → HYPERKALAEMIA.

Hyponatraemia may occur simultaneously.

13. Hypoaldosteronism

Other forms of hypoaldosteronism can also cause hyperkalaemia.

An important example is:

Hyporeninaemic hypoaldosteronism, often associated with diabetic kidney disease and type 4 renal tubular acidosis.

The characteristic pattern may include:

Hyperkalaemia + mild normal-anion-gap metabolic acidosis.

14. Spironolactone

Spironolactone is a mineralocorticoid receptor antagonist.

It blocks the action of:

Aldosterone.

This decreases potassium secretion in the collecting duct.

Therefore:

Spironolactone → K⁺ retention → hyperkalaemia.

The risk is greater in CKD or when combined with other drugs that suppress the renin–angiotensin–aldosterone system.

15. Amiloride

Amiloride blocks epithelial sodium channels:

ENaC

in the collecting duct.

This decreases the electrochemical gradient that normally promotes potassium secretion.

Therefore:

Amiloride → ↓ renal K⁺ secretion → hyperkalaemia.

16. ACE Inhibitors

ACE inhibitors reduce:

Angiotensin II

and consequently reduce:

Aldosterone secretion.

Therefore:

ACE inhibitor → ↓ aldosterone → ↓ K⁺ excretion → hyperkalaemia.

Examples include:

Ramipril.

Lisinopril.

Enalapril.

The risk increases in patients with:

CKD, diabetes, AKI or concurrent potassium-retaining medications.

17. Angiotensin Receptor Blockers

An important addition is:

ARBs, such as losartan.

Like ACE inhibitors, they reduce aldosterone activity and can therefore cause:

Hyperkalaemia.

18. NSAIDs

NSAIDs inhibit renal prostaglandin synthesis.

This can reduce renal perfusion and suppress:

Renin release.

Reduced renin leads to reduced aldosterone activity.

Therefore:

NSAIDs → ↓ renin/aldosterone + possible AKI → hyperkalaemia.

The risk is especially important in patients with pre-existing:

CKD or volume depletion.

19. Other Drugs Causing Hyperkalaemia

Important additional medications include:

Trimethoprim, which has an amiloride-like effect on ENaC.

Heparin, which can reduce aldosterone synthesis.

Tacrolimus and ciclosporin.

ARBs.

Potassium supplements.

Therefore unexplained hyperkalaemia should always trigger a:

Medication review.

20. Redistribution of Potassium

Most body potassium is normally located:

Inside cells.

Certain conditions cause potassium to move from the intracellular compartment into extracellular fluid.

This produces:

Redistribution hyperkalaemia.

Important examples include:

Acidosis.

Rhabdomyolysis.

Tumour lysis syndrome.

Digoxin toxicity.

Insulin deficiency and hyperglycaemic hyperosmolality can also contribute.

21. Acidosis

The original notes correctly include:

Acidosis.

In some forms of metabolic acidosis, particularly mineral/inorganic acid acidosis, extracellular H⁺ promotes movement of potassium out of cells.

Therefore:

H⁺ moves into cells

while:

K⁺ moves out

to help maintain electroneutrality.

This contributes to:

Hyperkalaemia.

22. Important Acidosis Clarification

The relationship between acidosis and potassium is not identical in every type of acidosis.

Hyperkalaemia is particularly associated with:

Mineral acidosis

and with conditions involving:

Insulin deficiency, hyperosmolality or impaired renal function.

Organic acidoses do not necessarily cause the same degree of direct H⁺/K⁺ exchange.

23. Rhabdomyolysis

Skeletal muscle cells contain large amounts of intracellular potassium.

In rhabdomyolysis:

Muscle cells break down.

↓

Intracellular K⁺ is released.

↓

Hyperkalaemia develops.

Other substances released include:

Myoglobin.

Phosphate.

Creatine kinase.

Hyperkalaemia may become especially severe if rhabdomyolysis also causes:

AKI.

24. Tumour Lysis Syndrome

Tumour lysis syndrome occurs when large numbers of malignant cells rapidly break down.

Cellular contents enter the circulation, producing:

Hyperkalaemia.

Hyperphosphataemia.

Hyperuricaemia.

Secondary:

Hypocalcaemia.

Therefore:

TUMOUR LYSIS → ↑ K⁺ + ↑ PHOSPHATE + ↑ URIC ACID + ↓ Ca²⁺.

25. Digoxin Toxicity

The original notes correctly include:

Digoxin poisoning.

Digoxin inhibits:

Na⁺/K⁺-ATPase.

In acute severe toxicity, potassium movement into cells is reduced.

Therefore extracellular potassium rises:

Acute digoxin toxicity → hyperkalaemia.

The degree of hyperkalaemia can be an important marker of severe acute toxicity.

26. ECG Changes in Hyperkalaemia

Hyperkalaemia alters myocardial depolarisation and repolarisation.

The traditional sequence is:

Peaked T waves

↓

PR prolongation

↓

P-wave flattening

↓

P-wave disappearance

↓

QRS widening

↓

Sine-wave pattern

↓

Ventricular fibrillation or asystole.

However, the ECG does not always progress predictably, and dangerous hyperkalaemia can occasionally exist without classic ECG changes.

27. Peaked T Waves

An early classic ECG manifestation is:

Tall, narrow, peaked or “tented” T waves.

These reflect altered ventricular:

Repolarisation.

They may be particularly prominent in the:

Precordial leads.

28. P-Wave Changes

As hyperkalaemia becomes more severe:

P-wave amplitude decreases.

This reflects impaired atrial conduction.

Eventually:

P waves may disappear completely.

29. PR Prolongation

The:

PR interval increases

as atrioventricular conduction slows.

Therefore:

Hyperkalaemia → conduction slowing → PR prolongation.

30. QRS Widening

Further elevation of potassium causes slowing of ventricular depolarisation.

Therefore:

QRS complexes become progressively wider.

Marked QRS widening is a dangerous sign of severe cardiac toxicity.

31. Sine-Wave Pattern

In extreme hyperkalaemia:

Widened QRS complexes merge with T waves.

This produces a:

Sine-wave or sinusoidal appearance.

This represents:

Pre-terminal cardiac toxicity

and may rapidly progress to:

Ventricular fibrillation or asystole.

32. ECG Changes – Note Form

T waves:

Tall + peaked + tented.

↓

P waves:

Become smaller.

↓

PR interval:

Prolongs.

↓

P waves:

May disappear.

↓

QRS:

Widens.

↓

QRS + T merge:

Sine-wave pattern.

↓

VF / asystole / cardiac arrest.

33. Treatment Principles

Treatment of severe hyperkalaemia can be understood as four separate objectives:

1. Protect the heart.

2. Shift potassium into cells.

3. Remove potassium from the body.

4. Identify and treat the underlying cause.

This framework is more useful than simply memorising a drug list.

34. Intravenous Calcium – Protect the Heart

The original notes correctly include:

Intravenous calcium gluconate.

Calcium antagonises the adverse electrophysiological effects of hyperkalaemia on cardiac tissue.

Therefore:

IV CALCIUM → STABILISES THE CARDIAC MEMBRANE.

35. Calcium Does Not Lower Potassium

This is extremely important:

CALCIUM DOES NOT REDUCE THE SERUM POTASSIUM CONCENTRATION.

Its purpose is to:

Protect the myocardium while other treatments lower potassium.

Its effect begins rapidly but is temporary.

36. Insulin and Dextrose – Shift Potassium Into Cells

The original notes correctly include:

Intravenous insulin + dextrose/glucose.

Insulin stimulates:

Na⁺/K⁺-ATPase

and drives potassium:

From extracellular fluid → into cells.

Therefore:

INSULIN → RAPID TEMPORARY FALL IN SERUM K⁺.

Glucose is usually administered to reduce the risk of:

Hypoglycaemia.

Blood glucose requires monitoring after treatment.

37. Nebulised Salbutamol

The original notes correctly include:

Salbutamol nebulisers.

Salbutamol is a:

β₂-adrenergic agonist.

β₂ stimulation increases Na⁺/K⁺-ATPase activity and shifts potassium:

Into cells.

Therefore nebulised salbutamol can provide an additional temporary reduction in:

Serum K⁺.

It should not be relied upon as the sole treatment for severe hyperkalaemia.

38. Sodium Bicarbonate

Sodium bicarbonate is not routinely effective for every case of hyperkalaemia.

However, it may be considered in selected patients with significant:

Metabolic acidosis.

Its potassium-lowering effect is less predictable than insulin.

39. Removing Potassium From the Body

Treatments such as:

Insulin

and

Salbutamol

mainly redistribute potassium into cells.

They do not remove substantial potassium from the body.

Definitive potassium removal may require:

Renal excretion.

Gastrointestinal potassium binders.

or

Dialysis.

40. Furosemide

The original notes include:

Furosemide.

This loop diuretic can increase urinary potassium excretion if the patient has:

Adequate renal function and urine production.

Therefore it may be useful in selected patients, particularly when volume overload is also present.

It will be much less useful in:

Severe oliguric or anuric kidney failure.

41. Calcium Resonium

The original notes include:

Calcium resonium, or calcium polystyrene sulfonate.

This is a gastrointestinal:

Cation-exchange resin.

It binds potassium in the gastrointestinal tract and promotes its removal in stool.

However, it has a relatively slow and variable effect and is:

Not appropriate as the sole emergency treatment of life-threatening hyperkalaemia.

42. Newer Potassium Binders

Modern potassium-lowering options also include agents such as:

Sodium zirconium cyclosilicate

and

Patiromer.

Their role depends on the urgency and clinical context. They do not replace immediate cardiac protection and intracellular shifting therapy when severe ECG-toxic hyperkalaemia is present.

43. Dialysis

Dialysis directly removes potassium from the bloodstream.

It is particularly important when hyperkalaemia is:

Severe.

Refractory to medical treatment.

Recurrent after temporary intracellular shifting.

or associated with:

Severe kidney failure.

Therefore:

REFRACTORY SEVERE HYPERKALAEMIA = IMPORTANT INDICATION FOR URGENT DIALYSIS.

44. Emergency Treatment – Note Form

STEP 1 – Protect the heart

ECG changes / severe hyperkalaemia

↓

IV calcium gluconate

↓

Cardiac membrane stabilisation.

↓

Does NOT lower K⁺.

STEP 2 – Shift K⁺ into cells

IV insulin + glucose

and/or

Nebulised salbutamol.

↓

Serum K⁺ falls temporarily.

STEP 3 – Remove K⁺ from body

Depending on circumstances:

Loop diuretic if kidneys can excrete K⁺.

Potassium-binding therapy.

Dialysis when severe/refractory or renal failure prevents adequate excretion.

STEP 4 – Treat the cause

Stop or review potassium-raising drugs.

Treat AKI.

Correct appropriate acid–base disturbance.

Treat rhabdomyolysis/tumour lysis.

Treat adrenal insufficiency when present.

45. Causes – Note Form

SPURIOUS:

Haemolysed blood sample.

Traumatic venepuncture.

Marked thrombocytosis/leukocytosis.

EXCESS POTASSIUM:

IV potassium.

Oral potassium supplements.

Potassium-rich salt substitutes.

Especially dangerous with impaired renal function.

DECREASED EXCRETION:

AKI, especially oliguria/anuria.

Advanced CKD.

Addison disease.

Hypoaldosteronism.

DRUGS:

Spironolactone.

Amiloride.

ACE inhibitors.

ARBs.

NSAIDs.

Trimethoprim.

Heparin.

Tacrolimus/ciclosporin.

Potassium supplements.

REDISTRIBUTION / CELL RELEASE:

Acidosis.

Insulin deficiency/hyperosmolality.

Rhabdomyolysis.

Tumour lysis syndrome.

Acute digoxin toxicity.

46. Important Corrections to the Original Notes

The original classification of:

“Excessive intake” under “spurious”

should be corrected.

Haemolysis → pseudohyperkalaemia.

Excessive potassium administration → true hyperkalaemia.

The older terms:

“Acute renal failure”

and

“Chronic renal failure”

are better replaced with:

Acute kidney injury – AKI

and

Chronic kidney disease – CKD.

The ECG sequence in the original notes is useful, but remember:

ECG changes do not correlate perfectly with the serum potassium concentration.

A normal-looking ECG does not reliably exclude dangerous hyperkalaemia.

The original treatment list is broadly correct, but it is much easier to remember according to purpose:

CALCIUM → PROTECTS HEART.

INSULIN/GLUCOSE → SHIFTS K⁺ INTO CELLS.

SALBUTAMOL → SHIFTS K⁺ INTO CELLS.

FUROSEMIDE → INCREASES RENAL K⁺ EXCRETION IF KIDNEYS FUNCTION.

POTASSIUM BINDERS → REMOVE K⁺ THROUGH GI TRACT.

DIALYSIS → DIRECTLY REMOVES K⁺.

Key Clinical Pattern

For rapid recall:

HYPERKALAEMIA = THINK KIDNEYS + DRUGS + ALDOSTERONE + CELL BREAKDOWN/SHIFT.

AKI / CKD → ↓ K⁺ EXCRETION.

SPIRONOLACTONE / AMILORIDE / ACEi / ARB / NSAID → K⁺ RETENTION.

ADDISON / HYPOALDOSTERONISM → ↓ ALDOSTERONE → K⁺ RETENTION.

RHABDOMYOLYSIS / TUMOUR LYSIS → CELL BREAKDOWN → K⁺ RELEASE.

ACIDOSIS → K⁺ SHIFT OUT OF CELLS.

For the ECG:

PEAKED T → PR PROLONGATION → P WAVES FLATTEN/DISAPPEAR → QRS WIDENS → SINE WAVE → ARREST.

For emergency treatment, remember:

CALCIUM = PROTECT THE HEART.

INSULIN + GLUCOSE = SHIFT K⁺ INTO CELLS.

SALBUTAMOL = SHIFT K⁺ INTO CELLS.

DIURETIC/BINDER = REMOVE K⁺ WHEN APPROPRIATE.

DIALYSIS = DEFINITIVE RAPID REMOVAL WHEN SEVERE OR REFRACTORY.

Medicine – Hypomagnesaemia

Hypomagnesaemia means an abnormally low concentration of magnesium in the blood. Magnesium is an important intracellular cation involved in neuromuscular function, cardiac electrical stability, enzyme activity, potassium regulation and calcium homeostasis.

Hypomagnesaemia is particularly important clinically because it frequently occurs together with:

Hypokalaemia – low K⁺

and

Hypocalcaemia – low Ca²⁺.

Severe deficiency can produce potentially life-threatening cardiac and neurological complications.

1. Normal Magnesium Physiology

Most magnesium in the body is located within:

Bone.

Muscle.

Other intracellular tissues.

Only a small proportion is present in extracellular fluid and measurable in serum.

Therefore, serum magnesium does not always perfectly reflect:

Total body magnesium stores.

2. Regulation of Magnesium

Magnesium balance depends mainly on:

Gastrointestinal absorption

and

Renal excretion.

The kidneys are particularly important because they can alter urinary magnesium excretion according to the body’s requirements.

Therefore hypomagnesaemia usually results from either:

Gastrointestinal magnesium loss

or

Renal magnesium wasting.

3. Hypomagnesaemia and Hypokalaemia

The original notes correctly state that hypomagnesaemia is commonly associated with:

Low K⁺.

Magnesium deficiency promotes renal potassium wasting.

Normally intracellular magnesium helps regulate potassium secretion through renal potassium channels.

When magnesium is deficient:

Renal K⁺ loss increases.

Therefore:

Hypomagnesaemia → renal potassium wasting → hypokalaemia.

4. Refractory Hypokalaemia

This relationship has an important clinical consequence.

If a patient has:

Hypokalaemia + hypomagnesaemia,

giving potassium alone may fail to correct the potassium concentration adequately.

Therefore:

REFRACTORY HYPOKALAEMIA → ALWAYS CONSIDER MAGNESIUM DEFICIENCY.

Magnesium replacement is often required before or alongside potassium replacement.

5. Hypomagnesaemia and Hypocalcaemia

Hypomagnesaemia can also produce:

Hypocalcaemia.

Severe magnesium deficiency interferes with:

Parathyroid hormone – PTH secretion

and can also cause:

Resistance to the actions of PTH.

The result is impaired calcium homeostasis.

Therefore:

Severe ↓ Mg²⁺ → ↓ PTH secretion/action → ↓ Ca²⁺.

6. Refractory Hypocalcaemia

As with potassium, calcium may be difficult to correct when significant magnesium deficiency remains untreated.

Therefore:

HYPOCALCAEMIA + HYPOKALAEMIA TOGETHER → CHECK MAGNESIUM.

This is a particularly useful clinical clue.

7. Neuromuscular Manifestations

Magnesium deficiency increases neuromuscular excitability.

Patients may develop:

Muscle cramps.

Muscle weakness.

Tremor.

Hyperreflexia.

Paraesthesiae.

Tetany.

Severe deficiency may cause:

Seizures – fits.

8. Paraesthesiae and Tetany

The original notes correctly include:

Paraesthesiae

and

Tetany.

Tetany may result from the combined effects of:

Magnesium deficiency

and associated:

Hypocalcaemia.

Patients may therefore develop tingling around the mouth or extremities, muscle spasms and increased neuromuscular irritability.

9. Seizures

Severe hypomagnesaemia can cause:

Seizures.

This occurs because magnesium plays an important role in stabilising neuronal membranes and regulating neuronal excitability.

Therefore severe magnesium deficiency should be considered among the metabolic causes of:

Acute seizures.

10. Cardiac Manifestations

One of the most important consequences of hypomagnesaemia is:

Cardiac electrical instability.

Magnesium participates in normal myocardial ion-channel function and cardiac repolarisation.

Deficiency therefore increases susceptibility to:

Cardiac arrhythmias.

11. Ventricular Arrhythmias

The original notes correctly associate hypomagnesaemia with:

Ventricular arrhythmias.

The risk becomes particularly important when hypomagnesaemia coexists with:

Hypokalaemia.

12. Torsades de Pointes

A particularly important association is:

Torsades de pointes.

This is a polymorphic ventricular tachycardia associated with:

QT prolongation.

Magnesium is therefore used therapeutically for torsades de pointes, even in some patients whose measured serum magnesium is not markedly reduced.

13. Causes of Hypomagnesaemia

The major mechanisms can be organised into:

Gastrointestinal loss or impaired absorption.

Renal magnesium loss.

Redistribution or metabolic causes.

Alcohol-related deficiency.

Drug-induced magnesium wasting.

14. Renal Magnesium Loss

The kidneys normally conserve magnesium when body stores are low.

If renal tubular handling is impaired, excessive magnesium is lost in:

Urine.

This produces:

Renal magnesium wasting.

Causes include certain medications, hypercalcaemia and inherited renal tubular disorders.

15. Gastrointestinal Loss

The gastrointestinal tract is another major source of magnesium loss.

Important causes include:

High-volume diarrhoea

and

Malabsorption.

16. High-Volume Diarrhoea

The original notes correctly include:

High-volume diarrhoea.

Prolonged diarrhoea causes direct gastrointestinal loss of magnesium.

It may simultaneously cause losses of:

Potassium.

Bicarbonate.

Water.

Therefore a patient with severe diarrhoea may develop:

Hypomagnesaemia + hypokalaemia + metabolic acidosis.

17. Malabsorption

Conditions causing chronic malabsorption can reduce intestinal magnesium absorption.

Examples include:

Coeliac disease.

Inflammatory bowel disease with significant intestinal involvement or resection.

Short-bowel syndrome.

Chronic severe diarrhoeal disorders.

Therefore chronic gastrointestinal disease may gradually deplete total body magnesium.

18. Hypercalcaemia

The original notes include:

Hypercalcaemia.

This is a recognised cause of renal magnesium wasting.

High calcium concentrations can interfere with magnesium reabsorption in the nephron, particularly in the:

Thick ascending limb of the loop of Henle.

Therefore:

Hypercalcaemia → ↑ renal Mg²⁺ loss → hypomagnesaemia.

19. Diabetic Ketoacidosis

The original notes correctly include:

Diabetic ketoacidosis – DKA.

Patients with DKA often have significant total-body electrolyte depletion due to:

Osmotic diuresis.

This causes urinary losses of:

Water.

Potassium.

Magnesium.

Phosphate.

20. Magnesium in DKA

Even when the initial serum magnesium is not dramatically low, the patient’s:

Total body magnesium stores may be depleted.

Treatment with insulin and correction of the metabolic disturbance can alter extracellular concentrations further.

Therefore electrolytes require careful monitoring during DKA treatment.

21. Alcohol

The original notes correctly identify:

Alcohol

as an important cause.

Chronic alcohol use can produce magnesium deficiency through several mechanisms.

These include:

Poor nutritional intake.

Gastrointestinal losses.

Renal magnesium wasting.

Associated pancreatitis or diarrhoea may contribute further.

22. Alcohol and Multiple Electrolyte Abnormalities

Patients with chronic heavy alcohol exposure may simultaneously develop:

Hypomagnesaemia.

Hypokalaemia.

Hypophosphataemia.

Other nutritional deficiencies may also coexist.

Therefore magnesium should be checked in patients with alcohol-related illness and unexplained electrolyte abnormalities.

23. Drug-Induced Hypomagnesaemia

Several medications can cause magnesium depletion by increasing:

Renal magnesium excretion

or reducing:

Intestinal magnesium absorption.

The original notes correctly include:

Loop/thiazide diuretics.

Aminoglycosides.

Cisplatin.

Ciclosporin.

24. Loop Diuretics

Loop diuretics such as:

Furosemide

reduce sodium, potassium and chloride reabsorption in the thick ascending limb.

They can also increase urinary loss of:

Magnesium

and

Calcium.

Therefore prolonged or intensive loop-diuretic treatment may contribute to:

Hypomagnesaemia.

25. Thiazide Diuretics

Thiazide diuretics can also increase:

Renal magnesium loss.

Chronic therapy may therefore produce:

Hypomagnesaemia, particularly in susceptible patients.

Remember the calcium distinction:

Loop diuretics → ↑ urinary Ca²⁺.

Thiazides → ↓ urinary Ca²⁺.

But both can contribute to:

Magnesium loss.

26. Aminoglycosides

Aminoglycoside antibiotics can cause renal tubular toxicity.

Examples include:

Gentamicin.

Amikacin.

Tobramycin.

Tubular injury can impair magnesium reabsorption and produce:

Renal magnesium wasting.

27. Cisplatin

The chemotherapy agent:

Cisplatin

is an important cause of hypomagnesaemia.

It can damage renal tubular cells and produce persistent:

Renal magnesium wasting.

The magnesium deficiency may sometimes persist even after cisplatin treatment has finished.

28. Ciclosporin

Ciclosporin can also promote renal magnesium loss.

This is particularly relevant in patients receiving:

Immunosuppressive therapy, including transplant recipients.

Other calcineurin inhibitors, particularly:

Tacrolimus,

can have a similar effect.

29. Proton-Pump Inhibitors – Important Additional Cause

A major modern addition to the original list is:

Proton-pump inhibitors – PPIs.

Long-term PPI therapy can occasionally cause significant hypomagnesaemia by impairing:

Intestinal magnesium absorption.

Examples include:

Omeprazole.

Esomeprazole.

Pantoprazole.

Therefore unexplained persistent hypomagnesaemia should prompt review of:

PPI use.

30. Inherited Renal Causes

Certain inherited renal tubular disorders also produce magnesium loss.

An important example is:

Gitelman syndrome.

Gitelman syndrome typically causes:

Hypokalaemia.

Metabolic alkalosis.

Hypomagnesaemia.

Hypocalciuria.

31. Gitelman Syndrome

The renal defect resembles chronic exposure to a:

Thiazide diuretic.

Therefore:

GITELMAN → LOW K⁺ + LOW Mg²⁺ + METABOLIC ALKALOSIS + LOW URINARY Ca²⁺.

This is a useful examination pattern.

32. Clinical Features – Note Form

Cardiac:

Ventricular arrhythmias.

QT abnormalities.

Torsades de pointes.

Neurological:

Seizures.

Tremor.

Hyperreflexia.

Neuromuscular:

Tetany.

Muscle cramps.

Paraesthesiae.

Weakness.

Associated biochemical abnormalities:

Hypokalaemia.

Hypocalcaemia.

33. Causes – Note Form

Gastrointestinal loss:

High-volume diarrhoea.

Malabsorption.

Short-bowel states.

Renal loss:

Renal tubular disorders.

Hypercalcaemia.

Metabolic:

DKA with osmotic diuresis.

Alcohol:

Poor intake + GI loss + renal wasting.

Drugs:

Loop diuretics.

Thiazide diuretics.

Aminoglycosides.

Cisplatin.

Ciclosporin.

Tacrolimus.

Long-term PPIs.

34. Investigation

When hypomagnesaemia is identified, assessment should include:

Serum magnesium.

Potassium.

Calcium.

Renal function.

Other electrolytes may also be appropriate depending on the clinical situation.

35. Distinguishing Renal From Gastrointestinal Loss

If the cause is uncertain, urinary magnesium measurements can help determine whether the kidneys are appropriately conserving magnesium.

Conceptually:

Low urinary Mg²⁺ in hypomagnesaemia → kidneys are conserving magnesium → consider GI loss or poor intake.

In contrast:

Inappropriately high urinary Mg²⁺ → renal magnesium wasting.

This distinction can help identify the underlying mechanism.

36. Treatment

Treatment depends on:

Severity.

Symptoms.

Underlying cause.

Renal function.

Mild or asymptomatic deficiency can often be treated with:

Oral magnesium replacement.

37. Severe or Symptomatic Hypomagnesaemia

Severe deficiency associated with:

Seizures.

Tetany.

Significant ventricular arrhythmias.

may require:

Intravenous magnesium, commonly magnesium sulfate, with appropriate monitoring.

The underlying cause should also be corrected.

38. Correct Associated Electrolyte Abnormalities

If the patient also has:

Hypokalaemia

or

Hypocalcaemia,

magnesium deficiency should be corrected because these abnormalities may otherwise remain:

Refractory to treatment.

Therefore:

LOW Mg²⁺ + LOW K⁺ → REPLACE Mg²⁺ AS WELL AS K⁺.

39. Important Clarifications to the Original Notes

The statement:

“Usually associated with low Ca²⁺ and low K⁺”

is useful clinically, although not every patient will have both abnormalities.

The mechanisms are different:

Low Mg²⁺ → renal K⁺ wasting → hypokalaemia.

Severe low Mg²⁺ → impaired PTH secretion/action → hypocalcaemia.

The listed manifestations:

Ventricular arrhythmias, fits, tetany and paraesthesiae

are correct.

A particularly important cardiac complication to remember is:

TORSADES DE POINTES.

The original causes are also appropriate:

Renal loss.

High-volume diarrhoea.

Malabsorption.

Hypercalcaemia.

DKA.

Alcohol.

Loop/thiazide diuretics.

Aminoglycosides.

Cisplatin.

Ciclosporin.

Important modern additions include:

PPIs, tacrolimus and inherited renal tubular disorders such as Gitelman syndrome.

Key Clinical Pattern

For rapid recall:

HYPOMAGNESAEMIA → NEUROMUSCULAR EXCITABILITY + CARDIAC INSTABILITY.

Think:

BRAIN → SEIZURES.

NERVES/MUSCLES → PARAESTHESIAE + TETANY + TREMOR.

HEART → VENTRICULAR ARRHYTHMIAS + TORSADES.

ELECTROLYTES → ↓ K⁺ + ↓ Ca²⁺.

For the mechanism:

LOW Mg²⁺ → RENAL K⁺ WASTING → REFRACTORY HYPOKALAEMIA.

SEVERE LOW Mg²⁺ → ↓ PTH SECRETION/ACTION → HYPOCALCAEMIA.

For causes:

GI LOSS → DIARRHOEA / MALABSORPTION.

RENAL LOSS → DIURETICS / AMINOGLYCOSIDES / CISPLATIN / CALCINEURIN INHIBITORS / HYPERCALCAEMIA.

METABOLIC → DKA.

ALCOHOL → POOR INTAKE + GI LOSS + RENAL WASTING.

DRUG ABSORPTION PROBLEM → LONG-TERM PPI USE.

And the high-yield clinical rule is:

HYPOKALAEMIA THAT WILL NOT CORRECT → CHECK AND CORRECT MAGNESIUM.